<!DOCTYPE html>
<!-- saved from url=(0083)https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm -->
<html class="" data-reactroot=""><script async="false" type="text/javascript" src="chrome-extension://fnjhmkhhmkbjkkabndcnnogagogbneec/in-page.js"></script><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><script src="./1137.放射治疗 - 搜狗科学百科_files/analytics.js.download" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app225.us.archive.org';v.server_ms=246;archive_analytics.send_pageview({});});</script>
<script type="text/javascript" src="./1137.放射治疗 - 搜狗科学百科_files/bundle-playback.js.download" charset="utf-8"></script>
<script type="text/javascript" src="./1137.放射治疗 - 搜狗科学百科_files/wombat.js.download" charset="utf-8"></script>
<script type="text/javascript">
  __wm.init("https://web.archive.org/web");
  __wm.wombat("https://baike.sogou.com/kexue/d11137.htm","20221028212143","https://web.archive.org/","web","/_static/",
	      "1666992103");
</script>
<link rel="stylesheet" type="text/css" href="./1137.放射治疗 - 搜狗科学百科_files/banner-styles.css">
<link rel="stylesheet" type="text/css" href="./1137.放射治疗 - 搜狗科学百科_files/iconochive.css">
<!-- End Wayback Rewrite JS Include -->
<meta name="save" content="history"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="baidu-site-verification" content="VWGb6TyYx8"><meta content="放射治疗 - 搜狗科学百科" name="keywords"><meta content="搜狗科学百科是一部有着平等、协作、分享、自由理念的网络科学全书，为每一个互联网用户创造一个涵盖所有领域知识、服务的中文知识性平台。" name="description"><meta http-equiv="x-dns-prefetch-control" content="on"><meta name="server" baike="235" ip="210" env="online"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://cache.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://hhy.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://pic.baike.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://ugc.qpic.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://xui.ptlogin2.qq.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://q1.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://q2.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://q3.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://q4.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://q.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://img01.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://img03.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212143/https://img04.sogoucdn.com/"><link rel="Shortcut Icon" href="https://web.archive.org/web/20221028212143im_/https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link rel="Bookmark" href="https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link href="./1137.放射治疗 - 搜狗科学百科_files/base_b849887.css" rel="stylesheet"><link href="./1137.放射治疗 - 搜狗科学百科_files/detail_378aed5.css" rel="stylesheet"><link href="./1137.放射治疗 - 搜狗科学百科_files/inviteAudit_7894507.css" rel="stylesheet"><link rel="stylesheet" href="./1137.放射治疗 - 搜狗科学百科_files/highlight.min.css"><title>放射治疗 - 搜狗科学百科</title><style>.onekey-close {
	position: absolute;
	top: 16px;
	right: 16px;
	width: 24px;
	height: 24px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	text-indent: -999em;
	background-size: 84px;
	background-position: -63px 0;
}

.onekey-login {
	position: absolute;
	top: 16.4%;
	left: 0;
	right: 0;
	width: 100%;
}

/* .onekey-login-img {
    width: 75px;
    height: 75px;
    background: url("https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/images/sprite_wap_baike.png") no-repeat;
    background-size: 100px 91px;
    background-position: 0 0;
    background-repeat: no-repeat;
    margin: 0 auto;
} */

.onekey-login-title {
	text-align: center;
	padding-bottom: 3px;
	font-size: 21px;
	font-weight: bold;
	line-height: 30px;
	color: #000;
}

.onekey-login-txt {
	text-align: center;
	font-family: PingFangSC;
	font-size: 14px;
	line-height: 20px;
	color: #8f8f8f;
}

.onekey-login-qq,
.onekey-login-wx,
.onekey-login-phone {
	display: block;
	width: 245px;
	height: 54px;
	border-radius: 45px;
	text-align: center;

	margin: 0 auto;
	font-size: 17px;
	line-height: 24px;
	color: #000;
	/* padding: 16px 77px; */
	border-radius: 12px;
	border: solid 1px #e0e0e0;
}
.onekey-qq-content,
.onekey-vx-content,
.onekey-phone-content {
	display: inline-block;
	margin-top: 16px;
}
.onekey-qq-content {
	padding: 0 5px;
}

.onekey-login-qq {
	margin-top: 48px;
	margin-bottom: 24px;
}

.onekey-login-qq:before {
	display: inline-block;
	content: "";
	width: 20px;
	height: 20px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 80px;
	background-position: -20px 0;
	vertical-align: top;
	margin: 17px 8px 0 0;
}

.onekey-login-wx {
	margin-bottom: 24px;
}

.onekey-login-wx:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: 0 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-login-phone {
}

.onekey-login-phone:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: -42px 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-fixed {
	z-index: 100;
	position: fixed;
	top: 0;
	bottom: 0;
	left: 0;
	right: 0;
	background: #fff;
	width: 100%;
	height: 100%;
}

.onekey-fixed.forbid {
	z-index: 100;
	position: fixed;
	top: auto;
	bottom: 68px;
	left: 9%;
	right: 0;
	background: rgba(0, 0, 0, 0.7);
	width: 82%;
	height: 43px;
	border-radius: 25px;
	color: #ffffff;
}
.onekey-login-title.forbid {
	text-align: center;
	padding-bottom: 3px;
	font-size: 14px;
	font-weight: normal;
	line-height: 30px;
	color: white;
}
</style><style>#login_mask {
  background: #000;
  opacity: 0.5;
  filter: alpha(opacity=50);
  position: fixed;
  /*fixed好像在哪个IE上有BUG，先用用*/
  left: 0;
  top: 0;
  z-index: 999;
  height: 100%;
}

#login_iframe_container {
  position: fixed;
  width: 550px;
  height: 360px;
  z-index: 1020;
  background-color: #ffffff;
}

@media screen and (max-width: 828px) {
  #login_iframe_container {
    top: 50% !important;
    left: 50% !important;
    transform: translate(-50%, -50%);
  }
}

#login_iframe_container.new-login {
  width: 550px;
  height: 360px;
  background-image: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/background_2a4a8a6.png);
}

#login_iframe_container.new-login.no-bg {
  background: #fff;
}

#login_iframe_container.new-login .login-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 30px;
  letter-spacing: 0.19px;
  color: #ffffff;
  margin-top: 62px;
}
#login_iframe_container.new-login .forbid-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 24px;
  letter-spacing: 0.19px;
  color: #333333;
  margin-top: 150px;
}

#login_iframe_container.new-login.no-bg .login-title {
  color: #333333;
}

#login_iframe_container.new-login .login-subtitle {
  width: 100%;
  height: 18px;
  line-height: 18px;
  font-size: 13px;
  letter-spacing: 0.08px;
  color: #ffffff;
  text-align: center;
  margin-top: 9px;
  margin-bottom: 43px;
}

#login_iframe_container.new-login.no-bg .login-subtitle {
  color: #999999;
}

#login_iframe_container.new-login .login-subtitle::before {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: -5px;
}

#login_iframe_container.new-login .login-subtitle::after {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: 5px;
}

#login_iframe_container.new-login.no-bg .login-subtitle::before {
  background-color: #999999;
}

#login_iframe_container.new-login.no-bg .login-subtitle::after {
  background-color: #999999;
}

#login_iframe_container.new-login .close-btn {
  position: absolute;
  top: 20px;
  right: 20px;
  width: 12px;
  height: 12px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -59px -10px;
  background-size: 81px 91px;
  cursor: pointer;
}

#login_iframe_container.new-login .login-btn {
  width: 220px;
  height: 47px;
  border-radius: 24px;
  border: solid 1px #dddddd;
  background-color: #ffffff;
  margin: 0 auto;
  margin-top: 28px;
  position: relative;
  display: block;
}

#login_iframe_container.new-login .login-btn .login-icon {
  position: absolute;
}

#login_iframe_container.new-login .login-btn .login-text {
  width: 61px;
  height: 47px;
  line-height: 47px;
  vertical-align: middle;
  font-size: 15px;
  letter-spacing: 0.1px;
  color: #666666;
  position: absolute;
  right: 62px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-icon {
  width: 22px;
  height: 27px;
  top: 10px;
  left: 67px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -54px;
  background-size: 81px 91px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-text {
  right: 59px;
}

#login_iframe_container.new-login .login-btn.wechat-btn .login-icon {
  width: 29px;
  height: 24px;
  top: 12px;
  left: 62px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -10px;
  background-size: 81px 91px;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style></head><body class=""><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
</style>
<script>__wm.rw(0);</script>
<div id="wm-ipp-base" lang="en" style="display: block; direction: ltr;">
</div><div id="wm-ipp-print">The Wayback Machine - https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm</div>
<script type="text/javascript">//<![CDATA[
__wm.bt(675,27,25,2,"web","https://baike.sogou.com/kexue/d11137.htm","20221028212143",1996,"/_static/",["/_static/css/banner-styles.css?v=S1zqJCYt","/_static/css/iconochive.css?v=qtvMKcIJ"], false);
  __wm.rw(1);
//]]></script>
<!-- END WAYBACK TOOLBAR INSERT --><script>window._gtag=window._gtag||{};window._gtag.shouldGrayed = false;if ('b42e2ed7c6b044aea94935a6823282fb') window._gtag.traceId = 'b42e2ed7c6b044aea94935a6823282fb';if ({"illegality":true}) window.userInfo = {"illegality":true};</script><div class="topnavbox"><ul class="topnav"><li><a href="https://web.archive.org/web/20221028212143/https://www.sogou.com/web?query=">网页</a></li><li><a href="https://web.archive.org/web/20221028212143/https://weixin.sogou.com/weixin?p=75351201">微信</a></li><li><a href="https://web.archive.org/web/20221028212143/https://zhihu.sogou.com/zhihu?p=75351218">知乎</a></li><li><a href="https://web.archive.org/web/20221028212143/https://pic.sogou.com/pics?query=">图片</a></li><li><a href="https://web.archive.org/web/20221028212143/https://v.sogou.com/v?query=">视频</a></li><li><a href="https://web.archive.org/web/20221028212143/https://mingyi.sogou.com/">医疗</a></li><li class="cur"><strong>科学</strong></li><li><a href="https://web.archive.org/web/20221028212143/https://hanyu.sogou.com/">汉语</a></li><li><a href="https://web.archive.org/web/20221028212143/https://wenwen.sogou.com/">问问</a></li><li><a href="https://web.archive.org/web/20221028212143/https://www.sogou.com/docs/more.htm">更多<span class="topraquo">»</span></a></li></ul></div><div id="header"><div class="header-wrap"><a class="header-logo" href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue"></a><div class="header-search"><div class="querybox" id="suggBox"><form><input id="searchInput" class="query" type="text" placeholder="搜科学领域专业百科词条" name="query" autocomplete="off" value="" control-id="ControlID-1"><a href="javascript:;" class="query-search"></a></form></div></div><div class="header-rgt"><span class="btn-header-rgt btn-edit" id="editLemma">创建</span><div class="header-user no-login"></div></div></div></div><div class="fixed-placeholder" style="visibility:none"></div><div id="container" class=""><div class="content lemma-level1"><div class="detail-title" id="abstract-title"><h1>放射治疗</h1><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#!" class="detail-edit">编辑</a></div><div class="section_content" data-id="14996359232880915"><div><p><b>放射治疗</b>或者<b>放射疗法</b>，通常缩写作<b>RT</b>，<b>RTx</b>或<b>XRT</b>，是一种使用电离辐射的疗法，通常作为癌症治疗的一部分，用于控制或杀死恶性肿瘤细胞，一般由线性加速器输送。如果作用于身体的某个区域，放射治疗或对多种癌症具有疗效。它也可以作为辅助治疗的一部分，以防止原发性恶性肿瘤（例如，早期乳腺癌）在切除手术后复发。放射疗法与化疗具有协同作用，在易感癌症的化疗前、中和后期都有使用。肿瘤学中与放射治疗相关的分支学科叫做<b>放射肿瘤学</b>。 </p>
<p>放射疗法通常应用于癌性肿瘤，因为它能够控制细胞生长。电离辐射通过破坏癌组织的脱氧核糖核酸，导致细胞死亡而起作用。为了避开正常组织（辐射必须穿过皮肤、器官等来治疗肿瘤），成形的辐射束从几个暴露角度瞄准，在肿瘤处相交，从而提供远大于周围健康组织的吸收剂量。除了肿瘤本身之外，如果引流淋巴结在临床或放射学上与肿瘤有关，或者存在亚临床恶性扩散的风险，则辐射场也可能覆盖引流淋巴结。考虑到日常变化和肿瘤内部运动的不确定性，肿瘤周围的正常组织边缘也需要覆盖。这些不确定性可能由内部运动（例如，呼吸和膀胱充盈）和外部皮肤标记相对于肿瘤位置的运动引起。 </p>
<p>放射肿瘤学是与放射处方有关的医学专业，不同于放射学，即放射在医学成像和诊断中的使用。放射疗法通常由放射肿瘤学家经处方给出，目的是治愈（“有疗效”）或作为辅助治疗。放射肿瘤学也可以用作姑息疗法（在不可能治愈并且以局部疾病控制或症状缓解为目的的情况下）或者作为治疗疗法（在该疗法具有生存益处并且有疗效的情况下）。放射疗法联合外科、化学疗法、激素疗法、免疫疗法，或与该四者重的几种联合的疗法也很常见。在某种程度上，大多数常见的癌症都可以用放射疗法治疗。 </p>
<p>具体治疗意图（治愈、辅助治疗、新辅助治疗、或姑息疗法）将取决于肿瘤类型、位置和分期以及患者的总体健康状况。全身照射（TBI）是一种骨髓移植前预处理的放射治疗技术。短距离放射治疗，即放射源放置在需要治疗的区域内或附近，是另一种形式的放射治疗，其能使健康组织在乳腺癌、前列腺癌和其他器官癌症手术过程中暴露最小化。放射疗法可以应用于几种非恶性疾病治疗，例如三叉神经痛、听神经瘤、严重甲状腺眼病、翼状胬肉、色素沉着绒毛结节性滑膜炎，也可以预防瘢痕增生，血管再狭窄，和异位骨化。限制放射疗法对于非恶性疾病治疗的部分原因在于辐射存在诱发癌症的风险。 </p></div></div><div id="catalog"><h2 class="title2">目录<a href="javascript:" class="detail-edit">编辑</a></h2><div class="catalog_wrap" style=""><ul class="catalog_list col3"><li><span class="order">1</span><a href="javascript:" data-level="1" data-id="14996359249658116">医疗用途</a></li><li><span class="order">2</span><a href="javascript:" data-level="1" data-id="14996359249658117">副作用</a></li><li class="secondary_catalog"><span>2.1 </span><a href="javascript:" data-id="14996359249658117">急性副作用</a></li><li class="secondary_catalog"><span>2.2 </span><a href="javascript:" data-id="14996359249658117">晚期副作用</a></li><li class="secondary_catalog"><span>2.3 </span><a href="javascript:" data-id="14996359249658117">累积副作用</a></li><li class="secondary_catalog"><span>2.4 </span><a href="javascript:" data-id="14996359249658117">对生殖的影响</a></li><li class="secondary_catalog"><span>2.5 </span><a href="javascript:" data-id="14996359249658117">对垂体系统的影响</a></li><li class="secondary_catalog"><span>2.6 </span><a href="javascript:" data-id="14996359249658117">放射治疗事故</a></li></ul><ul class="catalog_list col3"><li><span class="order">3</span><a href="javascript:" data-level="1" data-id="14996359249658118">用于非癌症疾病</a></li><li><span class="order">4</span><a href="javascript:" data-level="1" data-id="14996359249658119">技术</a></li><li class="secondary_catalog"><span>4.1 </span><a href="javascript:" data-id="14996359249658119">作用机理</a></li><li class="secondary_catalog"><span>4.2 </span><a href="javascript:" data-id="14996359249658119">剂量</a></li><li><span class="order">5</span><a href="javascript:" data-level="1" data-id="14996359266435337">类型</a></li><li class="secondary_catalog"><span>5.1 </span><a href="javascript:" data-id="14996359266435337">外束放射疗法</a></li><li class="secondary_catalog"><span>5.2 </span><a href="javascript:" data-id="14996359266435337">接触式X射线近距离放射疗法</a></li><li class="secondary_catalog"><span>5.3 </span><a href="javascript:" data-id="14996359266435337">近距离放射疗法（密封源放射疗法）</a></li></ul><ul class="catalog_list col3"><li class="secondary_catalog"><span>5.4 </span><a href="javascript:" data-id="14996359266435337">非密封源放射疗法（全身放射性同位素疗法）</a></li><li class="secondary_catalog"><span>5.5 </span><a href="javascript:" data-id="14996359266435337">术中放疗</a></li><li class="secondary_catalog"><span>5.6 </span><a href="javascript:" data-id="14996359266435337">深吸屏气</a></li><li><span class="order">6</span><a href="javascript:" data-level="1" data-id="14996359266435338">历史</a></li><li><span class="order">7</span><a href="javascript:" data-level="1" data-id="references">参考文献</a></li></ul></div></div><div id="paragraphs"><div><div id="par_14996359249658116"><h2 class="title">1 医疗用途<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img02.sogoucdn.com/app/a/200698/sogou_science_16722" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title">对一名患有弥漫性脑桥内神经胶质瘤的患者进行放射治疗，放射剂量用彩色编码。</div>   
        </div> <p></p><p></p> 
<p>不同的癌症对放射疗法有不同的反应。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_1" class="kx_ref">[1]</a></sup><sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_2" class="kx_ref">[2]</a></sup><sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_3" class="kx_ref">[3]</a></sup> </p>
<p>癌症对辐射的反应可用其辐射敏感性来描述。中等剂量的辐射会迅速杀死对辐射高度敏感的癌细胞，包括白血病、大多数淋巴瘤和生殖细胞肿瘤。大多数上皮癌放射敏感性不高，故而需要更高的放射剂量（60-70Gy）才能实现根治。某些类型的癌症具有明显的抗辐射能力，也就是说，所需剂量可能要远高于临床实践中的安全剂量，才能产生根治效果。肾细胞癌和黑素瘤通常被认为是抗辐射的，但对于许多转移性黑色素瘤患者而言，放射治疗仍然是一种姑息疗法。放射疗法联合免疫疗法的相关研究众多，且对于黑色素瘤和其他癌症的治疗展现出了一定前景。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_4" class="kx_ref">[4]</a></sup> </p>
<p>在实际临床实践中，区分特定肿瘤的放射敏感性（在某种意义上可以看作一项实验室检查）和癌症的放射“可治愈性”是很重要的。例如，白血病通常不能用放射疗法治愈，因为它们在全身各处均有散播。淋巴瘤如果局限于身体的一个区域，则可能是可以根治的。同样，许多常见的中度放射性反应肿瘤如果处于早期阶段，通常会接受治疗剂量的放射治疗。例如：非黑色素瘤皮肤癌、头颈癌、乳腺癌、非小细胞肺癌、宫颈癌、肛门癌和前列腺癌。转移性癌症通常无法用放射疗法治愈，因为不可能进行全身放疗。 </p>
<p>治疗前，通常会进行CT扫描以识别肿瘤和周围正常结构，并在患者体表绘制小的皮肤标记来引导治疗区域。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_5" class="kx_ref">[5]</a></sup>在这个阶段，病人的体位是至关重要的，因为在治疗过程中，病人必须被设置在相同的体位。为此，目前已开发了许多患者定位装置，包括可以固定患者体位的面罩和垫子。 </p>
<p>肿瘤对放射治疗的反应也与其大小有关。由于复杂的放射生物学，体积较大的肿瘤对辐射的反应弱于较小的肿瘤或镜检病变。为克服这种影响，有各种应对的治疗策略。最常见的一种是放射治疗前的手术切除。这在乳腺癌的治疗中最常见，广泛局部切除或乳房切除术，随后再行辅助放疗。另一种方法是在根治性放疗前用辅助放疗缩小肿瘤。第三种技术是通过在放射治疗过程中给予某些药物来提高癌症的放射敏感性。放射增敏药物包括：顺铂、尼莫唑和西妥昔单抗等。 </p>
<p>放射治疗的效果因不同类型的癌症和不同群体而异。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_6" class="kx_ref">[6]</a></sup>例如，对于保乳手术后的乳腺癌，已经发现放射治疗可将疾病复发率减半。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_7" class="kx_ref">[7]</a></sup> </p></div></div><div id="par_14996359249658117"><h2 class="title">2 副作用<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>放射疗法本身没有痛苦。许多低剂量的姑息疗法（例如，对骨转移瘤的放射疗法）仅产生微小副作用，甚至没有副作用。但由于治疗区域内的水肿压迫神经，在治疗后的几天内可能会出现短期疼痛发作。较高剂量可在治疗期间（急性副作用）、治疗后数月或数年（长期副作用）或再治疗后（累积副作用）导致不同的副作用。副作用的性质、严重程度和持续时间取决于接受辐射的器官、治疗本身（辐射类型、剂量、分级、同步化疗）和患者。 </p>
<p>大多数副作用是可以预测且在预料之中的。辐射的副作用通常局限于患者身体接受治疗的部位。且副作用是剂量依赖性的；例如，较高剂量的头颈部辐射可能与心血管并发症、甲状腺功能障碍和垂体轴功能障碍有关。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_8" class="kx_ref">[8]</a></sup>现代放射疗法旨在将副作用降至最低，并帮助患者理解和应对不可避免的副作用。 </p>
<p>目前已有报告的主要副作用是疲劳和皮肤刺激，如轻度至中度的灼伤。疲劳通常发生在治疗过程的中间，在治疗结束后会持续数周。受刺激的皮肤会愈合，但可能不会像以前那样有弹性。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_9" class="kx_ref">[9]</a></sup> </p> 
<h3>2.1 <span>急性副作用</span></h3> 
<dl>
 <dt>
  恶心和呕吐
 </dt> 
 <dd>
  这并非放射治疗的常见副作用，并且在机理上仅与胃或腹部的治疗（其通常在治疗后几小时发生反应）相关，或者与在治疗某些头颈部肿瘤期间对头部中某些产生恶心感的结构的放射治疗相关，最常见的是内耳的前庭。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_10" class="kx_ref">[10]</a></sup>和任何其他导致痛苦的治疗一样，有些患者在放疗期间会立即呕吐，或者是有想要呕吐的感觉，但这被认为是一种心理反应。任何原因的恶心都可以用止吐药来治疗。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_11" class="kx_ref">[11]</a></sup>
 </dd> 
 <dt>
  对上皮表面的损伤
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_12" class="kx_ref">[12]</a></sup>
 </dt> 
 <dd>
  上皮表面可能因放射治疗而受损。根据治疗区域，可能包括皮肤、口腔粘膜、咽、肠粘膜和输尿管。损伤的发生率和恢复率取决于上皮细胞的周转率。通常情况下，治疗几周后皮肤将开始呈现粉红色，并伴随疼痛。在治疗期间以及放射治疗结束后的一周内，反应可能会变得更加严重，皮肤可能会破裂。虽然这种湿性脱皮令人不适，但通常恢复很快。皮肤反应往往在皮肤有自然褶皱的区域更严重，例如女性乳房下、耳后和腹股沟。
 </dd> 
 <dt>
  口腔、喉咙和胃部疼痛
 </dt> 
 <dd>
  如果头部和颈部接受放疗，口腔和喉咙通常会出现暂时性疼痛和溃疡。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_13" class="kx_ref">[13]</a></sup>若病情严重，可能会影响吞咽，患者可能需要止痛药和营养支持/食物补充剂。如果直接治疗食道，或者更为常见的一种情况是在肺癌治疗过程中接受一定剂量的附带辐射，也会引发食道疼痛。当治疗肝脏恶性肿瘤和转移时，侧支辐射可能导致胃、胃或十二指肠壅积症
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_14" class="kx_ref">[14]</a></sup>
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_15" class="kx_ref">[15]</a></sup>这种附带辐射通常是由正在输注的放射性试剂的非靶向输送（回流）引起的。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_16" class="kx_ref">[16]</a></sup>可以使用放射技巧、技术和装置来降低这种不良副作用的发生。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_17" class="kx_ref">[17]</a></sup>
 </dd> 
 <dt>
  肠道不适
 </dt> 
 <dd>
  下肠道若直接接受放射治疗（直肠或肛门癌的治疗），或通过放射治疗暴露于其他骨盆结构（前列腺、膀胱、女性生殖道），可出现疼痛、腹泻和恶心等典型症状。
 </dd> 
 <dt>
  肿胀
 </dt> 
 <dd>
  作为一般炎症的一部分，软组织肿胀可能会在放射治疗中引起问题。在脑肿瘤和脑转移瘤治疗过程中尤其，特别是在尤其是在既存颅内压升高或肿瘤引起管腔几乎完全阻塞（例如气管或主支气管）的情况下。放射治疗之前可考虑手术干预。如果认为手术不必要或不适当，患者可在放射治疗期间接受类固醇治疗，以减少肿胀。
 </dd> 
 <dt>
  不孕不育
 </dt> 
 <dd>
  性腺（卵巢和睾丸）对辐射非常敏感。直接暴露于大多数正常治疗剂量的辐射后，它们可能无法产生配子。如果性腺不是主要治疗区域，则所有身体部位的治疗计划都应最大限度地减少（若无法完全排除）性腺的剂量。
 </dd>
</dl> 
<h3>2.2 <span>晚期副作用</span></h3> 
<p>晚期副作用发生在治疗后几个月到几年，且一般局限于治疗区域。通常是由血管和结缔组织细胞的损伤引起的。通过将治疗分散化，可以明显减少晚期副作用。 </p> 
<dl>
 <dt>
  纤维化
 </dt> 
 <dd>
  由于扩散结疤过程，经过辐照的组织随着时间的推移，其弹性往往会降低。
 </dd> 
 <dt>
  毛发脱落
 </dt> 
 <dd>
  接受辐射剂量超过1&nbsp;Gy的任何有毛发的皮肤都可能发生脱毛（脱发）。该种副作用仅发生在辐射场中。10 Gy单剂量导致的脱发可能是永久性的&nbsp;，但如果分次治疗，在剂量超过45&nbsp;Gy之前，可能不会发生永久性脱发。
 </dd> 
 <dt>
  干燥
 </dt> 
 <dd>
  唾液腺和泪腺的辐射耐受性约为30&nbsp;Gy（2&nbsp;Gy每次），这一剂量已经超过了大多数性头颈癌根治治疗所需的剂量。口干（口腔干燥）和眼睛干涩（干眼症）可能成为令人烦恼的长期问题，并严重降低患者的生存质量。同样，进行放疗后的皮肤（例如腋窝）的汗腺往往会失去作用，原本潮湿的阴道粘膜经骨盆照射后常会变得干燥。
 </dd> 
 <dt>
  淋巴水肿
 </dt> 
 <dd>
  淋巴水肿是一种局部液体滞留和组织肿胀的症状，可能是放射治疗期间淋巴系统持续受损造成的。这是乳腺癌放疗患者在手术后接受辅助腋窝放疗以清除腋窝淋巴结时最常报告的并发症。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_18" class="kx_ref">[18]</a></sup>
 </dd> 
 <dt>
  癌症
 </dt> 
 <dd>
  辐射是癌症的潜在原因，在极少数患者中可见继发性恶性肿瘤——通常不到1/1000。它通常发生在治疗后20-30年，尽管一些血液系统恶性肿瘤可能在5-10年内发展。在绝大多数情况下，这种风险要远远低于原发性癌症所带来的风险。作为副作用发生的癌症一般局限于患者接受治疗的区域。
 </dd> 
 <dt>
  心血管疾病
 </dt> 
 <dd>
  据既往乳腺癌放疗方案观察，辐射会增加心脏病和死亡的风险。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_19" class="kx_ref">[19]</a></sup>治疗性辐射将后续心血管事件（即心脏病发作或中风）的风险增加到正常人的1.5至4倍（包括加重因素）。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_20" class="kx_ref">[20]</a></sup>这种增加取决于剂量，也与放射治疗的剂量强度、体积和位置有关。
 </dd> 
 <dd>
  心血管晚期副作用被称为辐射诱发心脏病（RIHD）和辐射诱发血管疾病（RIVD）。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_21" class="kx_ref">[21]</a></sup>其症状是剂量依赖性的，包括心肌病、心肌纤维化、瓣膜性心脏病、冠状动脉疾病、异常心脏节律和外周动脉疾病。辐射诱导的纤维化、血管细胞损伤和氧化应激可导致上述和其他晚期副作用症状。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_21" class="kx_ref">[21]</a></sup>大多数辐射诱发的心血管疾病发生在治疗后10年或以后，使得因果关系的确定更加困难。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_20" class="kx_ref">[20]</a></sup>
 </dd> 
 <dt>
  认知能力下降
 </dt> 
 <dd>
  在对头部进行放射治疗可能会导致认知能力下降。这一副作用在5至11岁的幼儿中尤为明显。例如，已有研究发现，5岁儿童的智商在治疗后每年下降几个智商点。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_22" class="kx_ref">[22]</a></sup>
 </dd> 
 <dt>
  放射性肠道病
 </dt> 
 <dd>
  腹部和骨盆放射治疗后，胃肠道可能受损。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_23" class="kx_ref">[23]</a></sup>萎缩、纤维化和血管变化产生吸收不良、腹泻、脂肪泻、出血，其中胆汁酸腹泻和维生素B12 吸收不良通常是由于回肠受累引起的。骨盆辐射疾病包括放射性直肠炎，导致出血、腹泻和尿急，
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_24" class="kx_ref">[24]</a></sup>当膀胱受到影响时也可能引起放射性膀胱炎。
 </dd> 
 <dt>
  辐射诱发的多发性神经病
 </dt> 
 <dd>
  尽管放射治疗至关重要，但也可能损伤目标区域附近或输送路径内的神经，因为神经组织也对放射线敏感。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_25" class="kx_ref">[25]</a></sup>电离辐射引起的神经损伤分阶段发生，初始阶段为微血管损伤、毛细血管损伤和神经脱髓鞘。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_26" class="kx_ref">[26]</a></sup>随后的损伤包括血管收缩和神经压迫，这是由于辐射引起的不受控制的纤维组织生长。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_26" class="kx_ref">[26]</a></sup>辐射诱发的多发性神经病，ICD-10-CM代码G62.82 ，发生在大约1-5%接受放射治疗的患者中。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_26" class="kx_ref">[26]</a></sup>
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_25" class="kx_ref">[25]</a></sup>
 </dd> 
 <dd>
  根据照射区域的不同，后效应神经病变可能发生在中枢神经系统或周围神经系统。例如，在中枢神经系统中，颅神经损伤通常表现为发生在治疗后1-14年的视力丧失。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_26" class="kx_ref">[26]</a></sup>在PNS中，丛神经损伤表现为放射诱导的臂神经丛病变或放射诱导的腰骶神经丛病变，可在治疗后30年内出现。
  <sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_26" class="kx_ref">[26]</a></sup>
 </dd>
</dl> 
<h3>2.3 <span>累积副作用</span></h3> 
<p>不应将放疗产生的累积效应与长期效应混淆——当短期效应消失，长期效应为亚临床效应时，再辐射仍可能存在问题。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_27" class="kx_ref">[27]</a></sup>这些剂量由放射肿瘤学家计算，在随后的放射发生之前，要考虑许多因素。 </p> 
<h3>2.4 <span>对生殖的影响</span></h3> 
<p>受孕后两周内的放射疗法对于受精卵是致命的，但不会产生畸形。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_28" class="kx_ref">[28]</a></sup>怀孕期间高剂量辐射会导致胎儿先天异常、生长受损和智力残疾，并且后代患儿童白血病和其他肿瘤的风险可能会增加。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_28" class="kx_ref">[28]</a></sup> </p>
<p>在既往接受过放射治疗的男性中，治疗后配偶所生子女的遗传缺陷或先天性畸形似乎没有增加。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_28" class="kx_ref">[28]</a></sup>然而，使用辅助生殖技术和显微操作技术可能会增加这种风险。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_28" class="kx_ref">[28]</a></sup> </p> 
<h3>2.5 <span>对垂体系统的影响</span></h3> 
<p>垂体机能减退通常出现在鞍区和鞍旁肿瘤、鞍外脑肿瘤、头颈部肿瘤的放射治疗后以及全身性恶性肿瘤的放射治疗后。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_29" class="kx_ref">[29]</a></sup>辐射诱导的垂体机能减退主要影响生长激素和性腺激素<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_29" class="kx_ref">[29]</a></sup>的分泌。相比之下，促肾上腺皮质激素 （ACTH）和促甲状腺激素 （TSH）缺乏在辐射诱发的垂体机能减退中比较少见。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_29" class="kx_ref">[29]</a></sup>催乳素分泌的变化通常是轻微的，化疗后加压素缺乏则非常罕见。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_29" class="kx_ref">[29]</a></sup> </p> 
<h3>2.6 <span>放射治疗事故</span></h3> 
<p>一般有严格的程序来减少患者意外过度暴露于辐射的风险。然而，偶尔还是会有意外发生；例如，放射治疗机 Therac-25在1985年至1987年期间至少造成了六起事故，在这些事故中，患者被给予的剂量是预期剂量的一百倍；辐射过量直接导致两人死亡。从2005年到2010年，密苏里的一家医院在五年内造成了76名患者过度暴露（大多数是脑癌患者），原因是新的放射设备安装不正确。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_30" class="kx_ref">[30]</a></sup> </p>
<p>放射肿瘤学家、医学物理学家和放射治疗团队的其他成员正在努力消除这些罕见的医疗错误。ASTRO发起了一项名为“安全定位”的安全倡议，旨在记录全国范围内的错误，以便医生能够从每一例医疗错误中吸取教训，并防止其再次发生。ASTRO还发布了一个问题列表，供患者向医生询问辐射安全问题，以确保每种治疗尽可能安全。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_31" class="kx_ref">[31]</a></sup> </p></div></div><div id="par_14996359249658118"><h2 class="title">3 用于非癌症疾病<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img02.sogoucdn.com/app/a/200698/sogou_science_16724" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title">手表面放射治疗入口的射束眼视图，其中引线屏蔽切口放置在机器机架中</div>   
        </div> <p></p><p></p> 
<p>放射疗法可用于治疗早期的杜普伊特伦病和莱德尔软管病。当杜普伊特伦氏病处于结节和索状阶段或手指处于小于10度的最小变形阶段时，考虑使用放射治疗来防止疾病的进一步发展。在某些情况下，术后也使用放射疗法来防止疾病继续发展。低剂量辐射通常使用三戈瑞的辐射五天，休息三个月，再接受三戈瑞的辐射五天。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_32" class="kx_ref">[32]</a></sup> </p></div></div><div id="par_14996359249658119"><h2 class="title">4 技术<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><h3>4.1 <span>作用机理</span></h3> 
<p>放射疗法通过破坏癌细胞的脱氧核糖核酸发挥作用。这种DNA损伤是由光子或带电粒子这两种能量之一引起的。其可以对组成DNA链的原子产生直接或间接电离。间接电离是水电离的结果，可形成自由基，特别是羟基，然后破坏DNA。 </p>
<p>在光子治疗中，大多数辐射效应是通过自由基产生的。细胞具有修复单链和双链DNA 损伤的机制。其中双链DNA断裂更难修复，并可能导致显著的染色体异常和遗传缺失。靶向双链断裂增加了细胞死亡的可能性。癌细胞通常不太分化，更像是干细胞；它们比大多数健康的分化细胞繁殖更加旺盛，并且修复亚致死损伤的能力降低。单链DNA损伤可通过细胞分裂传递，而且癌细胞DNA的损伤会累积，导致细胞死亡或减缓其繁殖。 </p>
<p>光子放射治疗的一个主要限制是实体肿瘤细胞缺乏氧气。实体肿瘤的生长可能会超过其血液供应，从而处于低氧状态，称为缺氧。氧是一种强有力的放射增敏剂，通过形成破坏DNA的自由基来提高给定剂量辐射的有效性。缺氧环境中的肿瘤细胞对辐射损伤的抵抗力可能是正常氧气环境中的2到3倍。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_33" class="kx_ref">[33]</a></sup>许多研究致力于克服缺氧这一问题，包括使用高压氧气瓶、热疗（将血管扩张到肿瘤部位）、增氧后的血液替代品、低氧细胞放射增敏剂药物如米索尼达唑和甲硝唑以及低氧细胞毒素（组织毒素），如地拉帕胺。正在研究的新方法包括对使用氧扩散增强化合物，如反式西红花酸钠 （TSC）作为放射增敏剂，目前已进入临床前和临床研究阶段。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_34" class="kx_ref">[34]</a></sup> </p>
<p>带电粒子如质子和硼、碳和氖离子可以通过高LET （ 传能线密度）对癌细胞DNA造成直接损伤，并且具有独立于肿瘤氧供应的抗肿瘤效果，因为这些粒子主要通过直接能量转移发挥作用，通常可导致双链DNA断裂。由于质子和其他带电粒子的质量相对较大，它们在组织中的侧向散射很小（电子束不会扩展太多），从而可以聚焦在肿瘤形状上，仅向周围组织传递小剂量的副作用。利用布拉格尖峰效应，还可以使它们更精确地靶向肿瘤。关于IMRT高精度放射线疗法（IMRT）与带电粒子疗法的不同效果，请参见质子疗法。该程序减少了带电粒子辐射源治疗肿瘤时对健康组织的损伤，并限定了到达肿瘤后的组织损伤范围。相比之下，IMRT使用不带电荷的粒子导致其能量在离开身体时可能损害健康细胞。这种损伤不是治疗性的，会增加治疗副作用，并增加继发性癌症诱发的可能性。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_35" class="kx_ref">[35]</a></sup>任何极具破坏性的杂散电离，在有其他器官的紧密接近靶器官的情况下都十分危险（例如：头颈癌）。这种X射线照射对儿童尤其有害，因为他们的身体正在发育，并且在初次放疗后5年，将有30%的可能再次患恶性肿瘤。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_36" class="kx_ref">[36]</a></sup> </p> 
<h3>4.2 <span>剂量</span></h3> 
<p>光子放射治疗中使用的辐射量以戈瑞（Gy）计量，并且根据正在治疗的癌症的类型和阶段而变化。对于治疗性病例，实体上皮肿瘤的典型剂量范围为60-80&nbsp;Gy，而淋巴瘤用20-40&nbsp;Gy。 </p>
<p>预防性（辅助）剂量通常在45-60 Gy左右（每次 1.8–2&nbsp;Gy，乳腺癌、头颈癌。）当选择剂量时，放射肿瘤学家会考虑许多其他因素，包括患者是否正在接受化疗、伴随疾病、术前/术后是否进行放射治疗以及手术的成功程度。 </p>
<p>处方剂量的输送参数将在治疗计划（剂量测定法的一部分）中确定。治疗计划通常使用专门的治疗计划软件在专用计算机上执行。根据辐射输送方法，可以使用多个角度或辐射源来合计所需的总剂量。治疗规划者将通过设计将均匀的处方剂量输送到肿瘤，并将对周围健康组织的剂量降至最低。 </p>
<p>在放射治疗中，三维剂量分布可以使用称为凝胶剂量测定法的剂量测定法技术来评估。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_37" class="kx_ref">[37]</a></sup> </p> 
<dl>
 <dt>
  分次治疗
 </dt>
</dl> 
<p>基于几个重要因素，放疗的总剂量是分次的（随时间分布）。分词治疗使得正常细胞有时间恢复，而肿瘤细胞在多次放疗之间的修复效率通常较低。分次治疗还允许在一次治疗期间处于细胞周期相对抗辐射阶段的肿瘤细胞在给予下一次放疗之前循环进入周期的敏感阶段。类似地，长期或急性低氧（因此更耐辐射）的肿瘤细胞可能在组分之间重新充氧，从而提高肿瘤细胞的杀伤能力。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_38" class="kx_ref">[38]</a></sup> </p>
<p>分次治疗方案在不同的放射治疗中心之间，甚至在个别医生之间均可能不同。在北美、澳大利亚和欧洲，成年人的典型分次计划是1.8-2 Gy一次，一周五天，每天1 Gy。对于某些类型的癌症，将分期计划延长太长时间会使肿瘤开始重新生长，对于这些肿瘤类型，包括头颈和宫颈鳞状细胞癌，放射治疗优选在一定时间内完成。对于儿童，典型的分数大小可以是1.5-1.8&nbsp;Gy，因为较小的分次辐射剂量可以降低正常组织中迟发性副作用的发生率和严重性。 </p>
<p>在某些情况下，在接近疗程结束时，每天进行两次分次治疗。这种方案被称为伴随强化疗法或超分割，用于肿瘤较小时，因为小型的肿瘤再生更快，特别是头颈部的肿瘤。 </p>
<p>接受姑息性放疗治疗单纯疼痛性骨转移的患者不应接受超过一部分的放疗。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_39" class="kx_ref">[39]</a></sup>单次治疗提供了与多次治疗相当的疼痛缓解和发病率结果，对于预期寿命有限的患者，单次治疗是改善患者舒适度的最佳方法。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_39" class="kx_ref">[39]</a></sup> </p> 
<dl>
 <dt>
  分次治疗计划
 </dt>
</dl> 
<p>目前越来越多地使用，相关研究较多的分次计划是低分割。这是一种将总辐射剂量分成较大剂量的放射治疗。典型剂量因癌症类型而异，从2.2&nbsp;Gy至20&nbsp;Gy不等，后者的典型应用是颅内病变的立体定向治疗（立体定向消融体放疗，或SABR——也称为SBRT，或立体定向体放疗）或颅内病变的SRS（立体定向放射外科）。低分割的基本原理是利用一些肿瘤的放射敏感性，通过剥夺肿瘤原细胞繁殖所需的时间来降低局部复发的可能性。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_40" class="kx_ref">[40]</a></sup>值得一提的是，立体定向治疗旨在通过消融过程破坏克隆原细胞，即放疗的目的是直接破坏肿瘤细胞，而不是像常规放射治疗那样反复中断肿瘤细胞分裂（凋亡）的过程。 </p> 
<p><strong>基于目标灵敏度的剂量估计</strong></p> 
<p>不同类型的癌症具有不同的辐射敏感性。然而，基于活检样本的基因组或蛋白质组分析预测灵敏度十分困难。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_41" class="kx_ref">[41]</a></sup><sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_42" class="kx_ref">[42]</a></sup>目前已发现微生物中的辐射保护由锰和小有机代谢物的非酶复合物提供，这为基因组学和蛋白质组学提供了另一种方法。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_43" class="kx_ref">[43]</a></sup>科学家们发现锰的含量和变化（可通过电子顺磁共振测量）是辐射敏感性的良好预测因子，这一发现同样适用于人类细胞。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_44" class="kx_ref">[44]</a></sup>经证实，总细胞锰含量及其变化可推断的不同肿瘤细胞的放射敏感性，这一发现可能有助于制定更精确的放射剂量，改善癌症患者的治疗。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_45" class="kx_ref">[45]</a></sup> </p></div></div><div id="par_14996359266435337"><h2 class="title">5 类型<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>迄今为止，放射治疗的三种主要类型是： </p> 
<ul>
 <li>外束放射疗法 （EBRT或XRT）或远程疗法；</li> 
 <li>近距离放射疗法或密封源放射疗法；</li> 
 <li>全身放射性同位素疗法或未密封源放射疗法。</li>
</ul> 
<p>各种类型的差异与辐射源的位置有关；在体外，近距离治疗使用密封放射源精确放置在治疗区域，全身放射性同位素通过输注或口服给药。近距离治疗可以通过放射源的临时或永久放置实现。临时源的放置通常使用一种称为后装的技术。在后装过程中，通过外科手术将中空管或施放器放置在待治疗的器官中，并且在施放器植入后将放射源装入施放器中。这最大限度地减少了卫生保健人员的辐射暴露。 </p>
<p>粒子疗法是一种特殊的外束放射疗法，其中粒子是质子或更重的离子。 </p> 
<h3>5.1 <span>外束放射疗法</span></h3> 
<p>以下三节涉及X射线治疗。 </p> 
<p><strong>常规外束放射疗法</strong></p> 
<p></p><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img02.sogoucdn.com/app/a/200698/sogou_science_16727" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title">一种远程治疗辐射胶囊，由以下物质组成： 一个 符合国际标准的放射源容器 （通常为铅制品）， 一个扣环 一个远程治疗 ”源“， 包括 焊接在一起的两个嵌套不锈钢罐， 上下各有一个不锈钢盖子，包裹 一个防护性屏障（通常由铀或钨合金制成）， 以及一个装有放射源的圆柱体，通常是 钴-60。“放射源”的直径通常为 30 mm.</div>   
        </div> <p></p><p></p> 
<p>传统的外部束放射治疗（2DXRT）是通过使用产生高能X射线的千伏治疗X射线单元或医用直线加速器的二维束来进行的。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_46" class="kx_ref">[46]</a></sup><sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_47" class="kx_ref">[47]</a></sup>2DXRT主要由从多个方向导向患者的单束辐射组成：通常是正面或背面，以及两侧。 </p>
<p>此处的“传统”指的是在一个被称为模拟器的经过特别校准的诊断X光机上计划或模拟治疗的方式，因为它再现了直线加速器的动作（或有时通过目测），并对建立的辐射束排列（通常较好）进行调整，以实现所需的<i>治疗计划</i>。模拟的目的是精确地瞄准或定位要治疗的区域。这种技术已经很成熟，并且通常快速可靠。但人担忧的是，一些高剂量治疗可能需要考虑靠近目标肿瘤的健康组织的辐射毒性能力。 </p>
<p>类似问题的例子包括前列腺的化疗，考虑到相邻直肠的放射灵敏度，使用2DXRT计划，安全处方的剂量不容易实现肿瘤控制。在CT发明之前，医生和物理学家对传递给癌组织和健康组织的真实辐射剂量的了解有限。因此，三维适形放射治疗正在成为许多肿瘤部位的标准治疗方法。最近，还使用了其他形式的成像，包括磁共振成像、正电子发射断层扫描、SPECT和超声波。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_48" class="kx_ref">[48]</a></sup> </p> 
<p><strong>立体定向辐射</strong></p> 
<p>立体定向放射是一种特殊类型的外束放射治疗。它使用聚焦辐射束，通过分辨率极高的成像扫描确定肿瘤范围。放射肿瘤学家通常在神经外科医生的帮助下对大脑或脊柱中的肿瘤进行立体定向治疗。 </p>
<p>立体定向辐射有两种类型。一种是<b>立体定向放射外科手术，</b>即医生对大脑或脊柱使用单个或多个立体定向放射治疗。另一种是<b>立体定向身体放射疗法</b>（SBRT），是指对身体（如肺）进行一次或多次立体定向放射治疗。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_49" class="kx_ref">[49]</a></sup> </p>
<p>一些医生表示，立体定向治疗的一个优点是，与通常需要6-11周的传统治疗相比，立体定向治疗可以在更短的时间内向癌症输送适量的辐射。此外，治疗的准确性极高，降低辐射对健康组织的影响。立体定向治疗的一个问题是它们只适用于某些小肿瘤。 </p>
<p>立体定向治疗的名称可能有些令人困惑，因为许多医院称这种治疗为制造商的名字，而不是称之为SRS或SBRT。这些治疗的品牌（技术）包括Axesse、赛博刀、伽玛刀、诺瓦利斯、Primatom、Synergy、 X-刀、断层扫描、Trilogy和 truebam 。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_50" class="kx_ref">[50]</a></sup>随着设备制造商不断开发新的专门技术来治疗癌症，这个列表也随之改变。 </p> 
<p><strong>虚拟仿真和三维适形放射治疗</strong></p> 
<p>使用专门的CT和/或MRI扫描仪和规划软件在三维空间描绘肿瘤和相邻正常结构的能力彻底改变了放射治疗治疗的规划。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_51" class="kx_ref">[51]</a></sup> </p>
<p>虚拟仿真是放疗规划的最基本形式，相较传统X射线，它可以更精确地放置辐射束。传统X射线通常难以评估软组织结构，也难以保护正常组织。 </p>
<p>虚拟仿真的一个显著提升是<b>三维适形放射治疗，</b>使用多叶准直器 （MLC）和可变数量的光束，将每个辐射光束在束流方向观（BEV）上与肿瘤靶区轮廓相符合。当治疗区域符合肿瘤的形状时，辐射对周围正常组织的相对毒性降低，从而可以将比传统技术更高剂量的辐射递送到肿瘤。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_5" class="kx_ref">[5]</a></sup> </p> 
<p><strong>强度调制放射疗法（IMRT）</strong></p> 
<p></p><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img03.sogoucdn.com/app/a/200698/sogou_science_16729" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title">瓦里安 TruBeam 直线加速器，用于输送IMRT</div>   
        </div> <p></p><p></p> 
<p>强度调制放射疗法（IMRT）是一种先进的高精度辐射，是下一代三维阴极射线管。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_52" class="kx_ref">[52]</a></sup>IMRT还提高了使治疗体积符合凹形肿瘤形状的能力，<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_5" class="kx_ref">[5]</a></sup>例如当肿瘤包裹在诸如脊髓或主要器官或血管的脆弱结构周围时。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_53" class="kx_ref">[53]</a></sup>计算机控制的X射线加速器将精确的辐射剂量分配给恶性肿瘤或肿瘤内的特定区域。使用高度定制的计算应用程序来执行优化和治疗模拟（治疗计划）来确定辐射输送模式。通过控制或调节辐射束的强度，辐射剂量与肿瘤的三维形状一致。肿瘤靶区附近的辐射剂量强度增加，而相邻正常组织受到的辐射则可得到减少或完全避免。这样可以达到比3DCRT更好的肿瘤靶向性、更少的副作用和更好的治疗结果。 </p>
<p>3DCRT仍然广泛用于许多身体部位，但IMRT也越来越多地应用于更复杂的身体部位，如中枢神经系统、头颈部、前列腺、乳房和肺。但IMRT所受的限制之一是，需要有经验的医务人员，且花费更多时间。这是因为医生每次均必须通过手动方式在整个疾病部位描绘一幅CT图像，这可能比3DCRT准备时间长得多。随后，医学物理学家和剂量学家必须参与制定一个可行的治疗计划。此外，自20世纪90年代末以来，IMRT技术仅在商业上使用，即使在最先进的癌症中心也是如此，因此在实施IMRT计划之前，没有在住院学习期间学习过该项技术的放射肿瘤医生必须接受额外的培训。 </p>
<p>越来越多的证据表明，对于大多数肿瘤，上述两种技术中的任何一种都比传统放射治疗（2DXRT）更能提高存活率，并降低正常组织毒性。在皇家马斯登医院的克里斯托弗·纳特教授进行的一系列关键试验中，头颈癌尤其如此。这两种技术都能够增加剂量，并潜在地增加效用。但人们仍有顾虑，特别是对IMRT，<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_54" class="kx_ref">[54]</a></sup>正常组织辐射暴露量的增加以及随之而来的继发恶性肿瘤的可能性。对成像准确性的过度自信可能会增加病变遗漏的可能性，这些病变在计划扫描中是不可见的（因此不包括在治疗计划中），以及在治疗期间患者的移动（例如，由于呼吸或患者制动不充分）。目前正在开发新的技术来更好地控制这种不确定性——例如，实时成像与治疗光束的实时调整相结合。这项新技术被称为图像引导放射疗法 （IGRT）或四维放射疗法。 </p>
<p>另一种技术是实时跟踪和定位植入肿瘤内部或附近的一个或多个小型可植入电子设备。有各种类型的医用可植入装置用于此目的。其可以是一个磁性应答器，检测由几个发射线圈产生的磁场，然后将测量结果传输回定位系统以确定位置。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_55" class="kx_ref">[55]</a></sup>植入式设备也可以是发送射频信号的小型无线发射器，然后该射频信号将被传感器阵列接收并用于肿瘤位置的定位和实时跟踪。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_56" class="kx_ref">[56]</a></sup><sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_57" class="kx_ref">[57]</a></sup> </p> 
<p><strong>容积调制电弧疗法（VMAT）</strong></p> 
<p>容积调制电弧疗法（VMAT）是2007年引入的一种放射技术<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_58" class="kx_ref">[58]</a></sup>，其可以在目标肿瘤的覆盖和正常组织的分辨上实现高度适形的剂量分布。该技术的特异性来自治疗过程中对三个参数的修改。即通过旋转台架（通常是360个旋转场，带有一个或多个弧）、用多叶准直器（“滑动窗口”移动系统）改变光束的速度和形状以及医用直线加速器的通量输出率（剂量率）来传递辐射。与传统的静态场强调制放射疗法（IMRT）相比，VMAT在患者治疗方面具有减少放射输送时间的优势。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_59" class="kx_ref">[59]</a></sup><sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_60" class="kx_ref">[60]</a></sup>VMAT和传统IMRT在保存健康组织和高危器官方面的更多地取决于癌症类型。在治疗鼻咽癌、口咽癌和下咽癌时，VMAT可以提供与IMRT同等或更好的OAR保护。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_58" class="kx_ref">[58]</a></sup><sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_59" class="kx_ref">[59]</a></sup><sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_60" class="kx_ref">[60]</a></sup>在前列腺癌的治疗中，OAR的保护效果则各有不同。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_58" class="kx_ref">[58]</a></sup>一些研究显示VMAT更好，另一些研究则显示IMRT更好。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_61" class="kx_ref">[61]</a></sup> </p> 
<p><strong>粒子疗法</strong></p> 
<p>在粒子治疗中（例如质子治疗），将高能电离粒子（质子或碳离子）导向目标肿瘤。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_62" class="kx_ref">[62]</a></sup>当粒子穿透组织时，剂量增加，达到最大值（即布拉格尖峰）发生在粒子的末端附近范围，然后下降到（几乎）零。这种能量沉积分布的优点是仅有较少的能量沉积到目标组织周围的健康组织中。 </p> 
<p><strong>俄歇电子核素靶向疗法</strong></p> 
<p>俄歇疗法 （AT）使用非常高的剂量<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_63" class="kx_ref">[63]</a></sup>在原子尺度上提供分子修饰的电离辐射。AT在几个方面不同于传统的放射疗法；它既不依赖放射性核在细胞尺度上引起细胞辐射损伤，也不从多个方向通过多个外部辐射束向目标区域递送剂量，以减少目标组织/器官之外的辐射剂量。相反，使用AT在分子水平上原位递送非常高剂量的目的是作用于原位分子修饰，包括分子断裂和分子重排，例如堆叠结构的变化以及与所述分子结构相关的细胞代谢功能。 </p> 
<h3>5.2 <span>接触式X射线近距离放射疗法</span></h3> 
<p>接触式X射线近距离放射疗法（也称为“CXB”、“电子近距离放射疗法”或“巴比隆技术”）是一种使用千伏电压的放射疗法X射线贴在肿瘤附近进行治疗直肠癌的方式。该过程包括将射线管插入肛门，然后以高剂量的X射线直接发射到直肠肿瘤，每两周一次。这项技术通常用于治疗可能不适合手术的患者的早期直肠癌。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_64" class="kx_ref">[64]</a></sup><sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_65" class="kx_ref">[65]</a></sup><sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_66" class="kx_ref">[66]</a></sup>2015年NICE的一项审查发现，其主要副作用是约38%的病例发生出血，27%的病例发生辐射诱发的溃疡。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_64" class="kx_ref">[64]</a></sup> </p> 
<h3>5.3 <span>近距离放射疗法（密封源放射疗法）</span></h3> 
<p></p><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img04.sogoucdn.com/app/a/200698/sogou_science_16731" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title" style="text-align: center;">SAVI近距离放射治疗设备</div>   
        </div> <p></p><p></p> 
<p>近距离治疗是通过将放射源放置在需要治疗的区域内或附近来实施的。近距离放射治疗作为一种有效的疗法，通常被用于宫颈，<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_67" class="kx_ref">[67]</a></sup>前列腺，<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_68" class="kx_ref">[68]</a></sup>乳房，<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_69" class="kx_ref">[69]</a></sup>和皮肤癌<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_70" class="kx_ref">[70]</a></sup>，也可用于治疗许多其他身体部位的肿瘤。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_71" class="kx_ref">[71]</a></sup> </p>
<p>在近距离放疗中，放射源被精确地直接放置在癌性肿瘤的位置。这意味着辐射只影响非常局部的区域，这减少了远离放射源的健康组织的辐射暴露。近距离放射治疗的这些特点提供了优于外部束放射治疗的优势——可以用非常高剂量的局部放射治疗肿瘤，同时降低对周围健康组织不必要的损伤。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_71" class="kx_ref">[71]</a></sup><sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_72" class="kx_ref">[72]</a></sup>近距离治疗的过程通常可以在比其他放射治疗技术更短的时间内完成。这有助于减少在每次放射治疗剂量间隔期间存活的癌细胞分裂和生长的机会。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_72" class="kx_ref">[72]</a></sup> </p>
<p>乳房近距离放射疗法就是一个很好的局限放射的例子，SAVI装置通过多个导管输送辐射剂量，每个导管都可以单独控制。与外束放射治疗和旧的乳房近距离放射治疗方法相比，这种方法减少了健康组织的暴露和由此产生的副作用。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_73" class="kx_ref">[73]</a></sup> </p> 
<h3>5.4 <span>非密封源放射疗法（全身放射性同位素疗法）</span></h3> 
<p>系统性放射性同位素治疗（RIT）是一种靶向治疗。靶向可能是由于同位素的化学性质，如放射性碘，它可以被甲状腺特异性吸收，相较其他身体器官要高一千倍。靶向也可以通过将放射性同位素附着到另一个分子或抗体上以将其引导到靶组织来实现。放射性同位素通过灌输（进入血流）或直接摄入体内。例如注入间碘苄基胍治疗成神经细胞瘤，口服碘-131治疗甲状腺癌或者甲状腺毒症、以及激素结合镥-177和钇-90治疗神经内分泌肿瘤（肽受体放射性核素疗法）。 </p>
<p>另一个例子是将放射性钇-90或钬-166微球注入肝动脉，放射性栓塞肝肿瘤或肝转移。使用这些微球的治疗方法被称为“选择性内放射疗法”。微球直径约为30&nbsp;µm （人类头发直径的三分之一），并直接输送到向肿瘤供血的动脉中。这类治疗通过引导导管向上穿过腿部股动脉，再导航到所需的目标部位进行治疗。给肿瘤供血的血液会将微球直接运送到肿瘤，从而实现比传统全身化疗更具选择性的方法。目前有三种不同类型的微球： SIR-sphere ，TheraSphere 和QuiremSpheres。 </p>
<p>全身放射性同位素疗法的主要用途是治疗癌症的骨转移。放射性同位素选择性地转移到受损骨骼区域，并保留正常未受累的骨骼。通常用于治疗骨转移的同位素是镭-223 ，<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_74" class="kx_ref">[74]</a></sup> 锶-89 和钐（<sup>153</sup>lexidronam。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_75" class="kx_ref">[75]</a></sup> </p>
<p>2002年，美国食品和药物管理局 （FDA）批准了抗CD20 的 ibritummab tiuxetan （泽缬氨酸） 与钇-90缀合的单克隆抗体。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_76" class="kx_ref">[76]</a></sup>2003年，美国食品和药物管理局（FDA）批准了托西莫单抗/碘（<sup>131</sup>I） tositumomab方案（Bexxar），它是碘-131标记和未标记的抗CD20单克隆抗体的组合。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_77" class="kx_ref">[77]</a></sup>这些药物是第一批被称为放射免疫疗法的药物，它们被批准用于治疗难治性非霍吉金斯淋巴瘤。 </p> 
<h3>5.5 <span>术中放疗</span></h3> 
<p>术中放疗 （IORT）是将治疗水平的辐射施加到目标区域，例如癌症肿瘤，手术期间会将该区域直接暴露。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_78" class="kx_ref">[78]</a></sup> </p> 
<p><strong>基本原理</strong></p> 
<p>IORT的基本原理是将高剂量辐射精确地输送到目标区域，同时尽量减少在IORT期间被转移或屏蔽的周围组织的暴露。传统的放射技术，例如手术切除肿瘤后的外照射（EBRT）有几个缺点：即便使用现代放射治疗计划，由于伤口腔的复杂定位，经常会错过应该施加最高剂量的肿瘤床。此外，手术切除肿瘤和EBRT之间的延迟可能会令肿瘤细胞有机会重新增殖。这些潜在的有害影响可以通过将辐射更精确地传递到目标组织来避免，从而导致剩余肿瘤细胞的立即被杀死。另一方面是伤口液体对肿瘤细胞有刺激作用。已有研究发现IORT可以抑制伤口液体的刺激作用。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_79" class="kx_ref">[79]</a></sup> </p> 
<h3>5.6 <span>深吸屏气</span></h3> 
<p>深吸屏气（DIBH）是一种在限制心脏和肺部辐射暴露的同时进行放射治疗的方法。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_80" class="kx_ref">[80]</a></sup>它主要用于治疗左侧乳腺癌。这项技术包括患者在治疗期间屏住呼吸。包括两种基本方法：自由呼吸屏气和肺活量测量监测的深吸气屏气。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_81" class="kx_ref">[81]</a></sup> </p></div></div><div id="par_14996359266435338"><h2 class="title">6 历史<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img03.sogoucdn.com/app/a/200698/sogou_science_16732" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title">1910年肺结核的x线治疗。在20世纪20年代之前，人们还不了解辐射的危害，它被用来治疗各种疾病。</div>   
        </div> <p></p><p></p> 
<p>医学上使用放射疗法治疗癌症已经有100多年的历史，其最早可追溯到1895年威廉·伦琴发现X射线。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_82" class="kx_ref">[82]</a></sup> 埃米尔·格拉布（芝加哥）于1896年成为第一个使用X射线治疗癌症的美国医生。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_83" class="kx_ref">[83]</a></sup> </p>
<p>放射治疗这一领域在20世纪初开始发展，主要是由于诺贝尔奖获奖科学家玛丽·居里（1867-1934）在1898年发现了放射性元素钋和镭。这开启了医学治疗和研究的新时代。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_82" class="kx_ref">[82]</a></sup>在20世纪20年代，人们还不了解辐射暴露的危害，也很少使用防护措施。镭被认为具有广泛的治疗能力，放射疗法被应用于许多疾病。 </p>
<p>在第二次世界大战之前，放射治疗的唯一实际辐射源是镭的“放射物”，即氡气体和射线管。体外放射治疗（远程治疗）开始于世纪之交，电压相对较低（&lt; 150&nbsp;kV） X射线机。人们发现，虽然浅表肿瘤可以用低电压X射线治疗，但更具穿透性、更高能量的射线需要到达体内的肿瘤，需要更高的电压。于是在20世纪20年代，使用200-500万伏管电压的正交电压X射线应运而生。要到达埋藏最深的肿瘤而不将介入的皮肤和组织暴露在危险的辐射剂量下，需要能量为1兆伏或以上，称为“兆伏”辐射。要产生所需的兆伏X射线，就要用到电压在300-500万伏特的X射线管，这需要大量昂贵的设备。兆伏X射线设备最早建于20世纪30年代末，但由于成本有限，仅限于几家机构。第一个安装在圣巴塞洛缪医院，伦敦在1937年使用，直到1960年，使用了一个30英尺长的X射线管，重10吨。镭可以产生兆伏γ射线，但是由于其在矿石中的含量低，所以极其罕见和昂贵。1937年，全世界放射治疗用镭的供应量为50克，价值80万美元，按2005年美元的价值计算则为5000万美元。 </p>
<p>第二次世界大战期间曼哈顿计划促使了核反应堆的发明，这使得人造放射性同位素用于放射治疗成为可能。钴疗法，利用钴60（一种由反应堆中的普通钴金属辐照产生的放射性同位素）释放出的兆伏伽马射线进行的远距放射疗法，在20世纪50年代至80年代初彻底改变了这一领域。钴机器相对便宜、坚固且使用简单，但由于其5.27年的半衰期，机器中的钴大约每5年就要更换一次。 </p>
<p>自20世纪40年代开发的医用线性粒子加速器在20世纪80年代开始取代X射线和钴元素，旧的疗法日渐衰落。第一台医用直线加速器于1953年在伦敦的汉默史密斯医院使用。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_47" class="kx_ref">[47]</a></sup>直线加速器可以产生更高的能量，具有更多的准直光束，并且不会产生放射性废物以及随之而来的放射性同位素的处置问题。 </p>
<p>随着高弗雷·豪斯费尔德发明计算机断层扫描，1971年，三维规划成为可能，并创造了从二维到三维辐射传输的转变。基于CT的规划让医生可以使用患者解剖结构的轴向断层图像更精确地确定剂量分布。随着新成像技术的出现，包括磁共振成像（20世纪70年代）和正电子发射断层摄影术（PET，20世纪80年代），放射治疗已经从三维适形转移到IMRT高精度放射线疗法（IMRT）和图像引导放射疗法（IGRT）断层疗法。这些进展使放射肿瘤学家能够更好地观察和定位肿瘤，从而获得更好的治疗效果、更多地保存患者器官保存以及更少的副作用。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_84" class="kx_ref">[84]</a></sup> </p>
<p>虽然在全球范围内放射治疗的普及率正在增加，但截至2017年，低收入和中等收入国家仍有一半以上的患者无法获得治疗。<sup><a href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/d11137.htm#quote_85" class="kx_ref">[85]</a></sup> </p></div></div></div></div><div id="references"><h2 class="title" id="par_references">参考文献</h2><ul class="references"><li id="quote_1"><span class="references-num">[1]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">CK·博姆福德，IH·昆克尔，J·沃尔特。沃尔特和米勒的放射疗法教科书(第6版)，p311.</span></p></li><li id="quote_2"><span class="references-num">[2]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">GP笔记本上的“辐射敏感性”http://www.gpnotebook.co.uk/simplepage.cfm?ID=2060451853.</span></p></li><li id="quote_3"><span class="references-num">[3]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">patient.co.uk http://patient.info/doctor/radiotherapy 的“放射疗法——全球定位系统需要知道什么”.</span></p></li><li id="quote_4"><span class="references-num">[4]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F (2015). "Metastatic melanoma - a review of current and future treatment options". Acta Derm Venereol. 95 (5): 516–524. doi:10.2340/00015555-2035. PMID 25520039..</span></p></li><li id="quote_5"><span class="references-num">[5]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">坎普豪森·卡，劳伦斯研究中心。《放射治疗原理》，帕兹杜尔R，瓦格纳LD，坎普豪森KA，霍斯金斯WJ(编辑)《癌症管理:多学科方法》。11版。2008..</span></p></li><li id="quote_6"><span class="references-num">[6]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Seidlitz, Annekatrin; Combs, Stephanie E.; Debus, Jürgen; Baumann, Michael (2016). "Practice points for radiation oncology". In Kerr, David J.; Haller, Daniel G.; van de Velde, Cornelis J. H.; Baumann, Michael. Oxford Textbook of Oncology (in 英语). Oxford University Press. p. 173. ISBN 9780191065101..</span></p></li><li id="quote_7"><span class="references-num">[7]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Darby, S.; McGale, P.; Correa, C.; Taylor, C.; Arriagada, R.; Clarke, M.; Cutter, D.; Davies, C.; Ewertz, M.; Godwin, J.; Gray, R.; Pierce, L.; Whelan, T.; Wang, Y.; Peto, R. (November 2011). "Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials". The Lancet. 378 (9804): 1707–1716. doi:10.1016/S0140-6736(11)61629-2. PMC 3254252. PMID 22019144..</span></p></li><li id="quote_8"><span class="references-num">[8]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Mahmood SS (2016). "Cardiovascular Complications of Cranial and Neck Radiation". Current Treatment Options in Cardiovascular Medicine. 18 (45): 45. doi:10.1007/s11936-016-0468-4. PMID 27181400..</span></p></li><li id="quote_9"><span class="references-num">[9]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Radiation Therapy for Breast Cancer: Possible Side Effects". Rtanswers.com. 2012-03-15. Archived from the original on 2012-03-01. Retrieved 2012-04-20..</span></p></li><li id="quote_10"><span class="references-num">[10]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Lee VH, Ng SC, Leung TW, Au GK, Kwong DL (2012). "Dosimetric predictors of radiation-induced acute nausea and vomiting in IMRT for nasopharyngeal cancer". International Journal of Radiation Oncology, Biology, Physics. 84 (1): 176–82. doi:10.1016/j.ijrobp.2011.10.010. PMID 22245210..</span></p></li><li id="quote_11"><span class="references-num">[11]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Archived copy". Archived from the original on 2012-03-30. Retrieved 2012-05-02.CS1 maint: Archived copy as title (link)常见辐射副作用.</span></p></li><li id="quote_12"><span class="references-num">[12]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Radiation Therapy Side Effects and Ways to Manage them". National Cancer Institute. 2007-04-20. Retrieved 2012-05-02..</span></p></li><li id="quote_13"><span class="references-num">[13]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hall, Eric J. (2000). Radiobiology for the radiologist. Philadelphia: Lippincott Williams Wilkins. p. 351. ISBN 9780781726498..</span></p></li><li id="quote_14"><span class="references-num">[14]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I, De la Riva S, Sola J, Bilbao JI, de Luis E, Sangro B (2007). "Gastroduodenal injury after radioembolization of hepatic tumors". The American Journal of Gastroenterology. 102 (6): 1216–20. doi:10.1111/j.1572-0241.2007.01172.x. PMID 17355414..</span></p></li><li id="quote_15"><span class="references-num">[15]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Yip D, Allen R, Ashton C, Jain S (2004). "Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer". Journal of Gastroenterology and Hepatology. 19 (3): 347–9. doi:10.1111/j.1440-1746.2003.03322.x. PMID 14748889..</span></p></li><li id="quote_16"><span class="references-num">[16]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, Nunez R, Habbu A, Liu D, Ross W, Cohen AM, Censullo M (2007). "Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy". Journal of Vascular and Interventional Radiology : JVIR. 18 (4): 553–61, quiz 562. doi:10.1016/j.jvir.2007.02.002. PMID 17446547..</span></p></li><li id="quote_17"><span class="references-num">[17]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Arepally A, Chomas J, Kraitchman D, Hong K (2013). "Quantification and reduction of reflux during embolotherapy using an antireflux catheter and tantalum microspheres: Ex vivo analysis". Journal of Vascular and Interventional Radiology : JVIR. 24 (4): 575–80. doi:10.1016/j.jvir.2012.12.018. PMID 23462064..</span></p></li><li id="quote_18"><span class="references-num">[18]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Meek AG (1998). "Breast radiation therapy and lymphedema". Cancer. 83 (12 Suppl American): 2788–97. doi:10.1002/(SICI)1097-0142(19981215)83:12B+&lt;2788::AID-CNCR27&gt;3.0.CO;2-I. PMID 9874399..</span></p></li><li id="quote_19"><span class="references-num">[19]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Taylor CW, Nisbet A, McGale P, Darby SC (December 2007). "Cardiac exposures in breast cancer radiotherapy: 1950s-1990s". International Journal of Radiation Oncology, Biology, Physics. 69 (5): 1484–95. doi:10.1016/j.ijrobp.2007.05.034. PMID 18035211..</span></p></li><li id="quote_20"><span class="references-num">[20]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Weintraub NL, Jones WK, Manka D (March 2010). "Understanding radiation-induced vascular disease". Journal of the American College of Cardiology. 55 (12): 1237–9. doi:10.1016/j.jacc.2009.11.053. PMC 3807611. PMID 20298931..</span></p></li><li id="quote_21"><span class="references-num">[21]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Klee NS, McCarthy CG, Martinez-Quinones P, Webb RC (November 2017). "Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy". Therapeutic Advances in Cardiovascular Disease. 11 (11): 297–317. doi:10.1177/1753944717729141. PMC 5933669. PMID 28911261..</span></p></li><li id="quote_22"><span class="references-num">[22]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Late Effects of Treatment for Childhood Cancer". National Cancer Institute. 12 April 2012. Retrieved 7 June 2012..</span></p></li><li id="quote_23"><span class="references-num">[23]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hauer-Jensen M, Denham JW, Andreyev HJ (2014). "Radiation enteropathy--pathogenesis, treatment and prevention". Nat Rev Gastroenterol Hepatol. 11 (8): 470–9. doi:10.1038/nrgastro.2014.46. PMC 4346191. PMID 24686268..</span></p></li><li id="quote_24"><span class="references-num">[24]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Fuccio L, Guido A, Andreyev HJ (2012). "Management of intestinal complications in patients with pelvic radiation disease". Clin. Gastroenterol. Hepatol. 10 (12): 1326–1334.e4. doi:10.1016/j.cgh.2012.07.017. PMID 22858731..</span></p></li><li id="quote_25"><span class="references-num">[25]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Christian Custodio; Cody Christian Andrews (August 1, 2017). "Radiation Plexopathy". American Academy of Physical Medicine and Rehabilitation..</span></p></li><li id="quote_26"><span class="references-num">[26]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Delanian S, Lefaix JL, Pradat PF (December 2012). "Radiation-induced neuropathy in cancer survivors". Radiotherapy and Oncology. 105 (3): 273–82. doi:10.1016/j.radonc.2012.10.012. PMID 23245644..</span></p></li><li id="quote_27"><span class="references-num">[27]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Nieder C, Milas L, Ang KK (2000). "Tissue tolerance to reirradiation". Semin Radiat Oncol. 10 (3): 200–9. doi:10.1053/srao.2000.6593. PMID 11034631..</span></p></li><li id="quote_28"><span class="references-num">[28]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Arnon J, Meirow D, Lewis-Roness H, Ornoy A (2001). "Genetic and teratogenic effects of cancer treatments on gametes and embryos". Human Reproduction Update. 7 (4): 394–403. doi:10.1093/humupd/7.4.394. PMID 11476352. [1].</span></p></li><li id="quote_29"><span class="references-num">[29]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Fernandez A, Brada M, Zabuliene L, Karavitaki N, Wass JA (September 2009). "Radiation-induced hypopituitarism" (PDF). Endocr. Relat. Cancer. 16 (3): 733–72. doi:10.1677/ERC-08-0231. PMID 19498038..</span></p></li><li id="quote_30"><span class="references-num">[30]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bogdanich W, Ruiz RR (25 February 2010). "Missouri Hospital Reports Errors in Radiation Doses". The New York Times. Retrieved 26 February 2010..</span></p></li><li id="quote_31"><span class="references-num">[31]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"What Questions Should I Ask My Doctor?: Questions to ask after treatment ends". Rtanswers.com. 2010-09-22. Archived from the original on 2012-04-12. Retrieved 2012-04-20..</span></p></li><li id="quote_32"><span class="references-num">[32]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Eaton C, Seegenschmiedt MH, Bayat A, Gabbiani G, Werker P, Wach W (2012). Dupuytren's Disease and Related Hyperproliferative Disorders: Principles, Research, and Clinical Perspectives. Springer. pp. 355–364. ISBN 978-3-642-22696-0..</span></p></li><li id="quote_33"><span class="references-num">[33]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D (2002). "Impact of tumor hypoxia and anemia on radiation therapy outcomes". Oncologist. 7 (6): 492–508. doi:10.1634/theoncologist.7-6-492. PMID 12490737..</span></p></li><li id="quote_34"><span class="references-num">[34]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Sheehan JP, Shaffrey ME, Gupta B, Larner J, Rich JN, Park DM (2010). "Improving the radiosensitivity of radioresistant and hypoxic glioblastoma". Future Oncology. 6 (10): 1591–1601. doi:10.2217/fon.10.123. PMID 21062158..</span></p></li><li id="quote_35"><span class="references-num">[35]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">柯蒂斯·雷、弗里德曼·DM、罗恩·E、里斯·拉格、哈克·DG、爱德华兹·BK、塔克·马、小弗劳米尼·JF(编辑)。癌症幸存者中的新恶性肿瘤:SEER癌症登记处，1973-2000。国家癌症研究所。NIH Publ。号码05-5302。马里兰州贝塞斯达，2006年。.</span></p></li><li id="quote_36"><span class="references-num">[36]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">https://web.archive.org/web/20221028212143/http://www . Helmholtz-muen Chen . de/file admin/ISS/PDF/Riiskoanalyse/乔治敦/Robison.pdf.</span></p></li><li id="quote_37"><span class="references-num">[37]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Baldock C, De Deene Y, Doran S, Ibbott G, Jirasek A, Lepage M, McAuley KB, Oldham M, Schreiner LJ (2010). "Polymer gel dosimetry". Physics in Medicine and Biology. 55 (5): R1–63. Bibcode:2010PMB....55R...1B. doi:10.1088/0031-9155/55/5/r01. PMC 3031873. PMID 20150687..</span></p></li><li id="quote_38"><span class="references-num">[38]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ang, K. Kian (October 1998). "Altered fractionation trials in head and neck cancer". Seminars in Radiation Oncology. 8 (4): 230–236. doi:10.1016/S1053-4296(98)80020-9..</span></p></li><li id="quote_39"><span class="references-num">[39]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">American Academy of Hospice and Palliative Medicine, "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Academy of Hospice and Palliative Medicine, retrieved August 1, 2013，引用了 Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, Howell D, Konski A, Kachnic L, Lo S, Sahgal A, Silverman L, von Gunten C, Mendel E, Vassil A, Bruner DW, Hartsell W, American Society for Radiation Oncology (ASTRO) (2011). "Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline". International Journal of Radiation Oncology*Biology*Physics. 79 (4): 965–976. doi:10.1016/j.ijrobp.2010.11.026. PMID 21277118..</span></p></li><li id="quote_40"><span class="references-num">[40]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">[·波拉克、艾伦和曼苏尔·艾哈迈德。低分馏:科学概念和临床经验。1号。埃利科特城:极限出版社，2011年].</span></p></li><li id="quote_41"><span class="references-num">[41]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF (February 2017). "A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study". The Lancet. Oncology. 18 (2): 202–211. doi:10.1016/S1470-2045(16)30648-9. PMID 27993569..</span></p></li><li id="quote_42"><span class="references-num">[42]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Lacombe J, Azria D, Mange A, Solassol J (February 2013). "Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes". Expert Review of Proteomics. 10 (1): 33–42. doi:10.1586/epr.12.68. PMID 23414358..</span></p></li><li id="quote_43"><span class="references-num">[43]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Daly MJ (March 2009). "A new perspective on radiation resistance based on Deinococcus radiodurans". Nature Reviews. Microbiology. 7 (3): 237–45. doi:10.1038/nrmicro2073. PMID 19172147..</span></p></li><li id="quote_44"><span class="references-num">[44]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Sharma A, Gaidamakova EK, Grichenko O, Matrosova VY, Hoeke V, Klimenkova P, Conze IH, Volpe RP, Tkavc R, Gostinčar C, Gunde-Cimerman N, DiRuggiero J, Shuryak I, Ozarowski A, Hoffman BM, Daly MJ (October 2017). "2+, gauged by paramagnetic resonance". Proceedings of the National Academy of Sciences of the United States of America. 114 (44): E9253–E9260. doi:10.1073/pnas.1713608114. PMC 5676931. PMID 29042516..</span></p></li><li id="quote_45"><span class="references-num">[45]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Doble PA, Miklos GL (July 2018). "Distributions of manganese in diverse human cancers provide insights into tumour radioresistance". Metallomics. 10 (9): 1191–1210. doi:10.1039/c8mt00110c. PMID 30027971..</span></p></li><li id="quote_46"><span class="references-num">[46]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hill R, Healy B, Holloway L, Kuncic Z, Thwaites D, Baldock C (March 2014). "Advances in kilovoltage x-ray beam dosimetry". Physics in Medicine and Biology. 59 (6): R183–231. Bibcode:2014PMB....59R.183H. doi:10.1088/0031-9155/59/6/R183. PMID 24584183..</span></p></li><li id="quote_47"><span class="references-num">[47]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Thwaites DI, Tuohy JB (July 2006). "Back to the future: the history and development of the clinical linear accelerator". Physics in Medicine and Biology. 51 (13): R343–62. Bibcode:2006PMB....51R.343T. doi:10.1088/0031-9155/51/13/R20. PMID 16790912..</span></p></li><li id="quote_48"><span class="references-num">[48]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Lagendijk JJ, Raaymakers BW, Van den Berg CA, Moerland MA, Philippens ME, van Vulpen M (November 2014). "MR guidance in radiotherapy". Physics in Medicine and Biology. 59 (21): R349–69. Bibcode:2014PMB....59R.349L. doi:10.1088/0031-9155/59/21/R349. PMID 25322150..</span></p></li><li id="quote_49"><span class="references-num">[49]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"American Society for Radiation Oncology" (PDF). Astro.org. Archived from the original (PDF) on 2010-06-13. Retrieved 2012-04-20..</span></p></li><li id="quote_50"><span class="references-num">[50]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Treatment Types: Stereotactic Radiation Therapy". Rtanswers.com. 2010-01-04. Archived from the original on 2012-05-09. Retrieved 2012-04-20..</span></p></li><li id="quote_51"><span class="references-num">[51]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bucci MK, Bevan A, Roach M (2005). "Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond". CA Cancer J Clin. 55 (2): 117–34. doi:10.3322/canjclin.55.2.117. PMID 15761080..</span></p></li><li id="quote_52"><span class="references-num">[52]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Galvin JM, Ezzell G, Eisbrauch A, Yu C, Butler B, Xiao Y, Rosen I, Rosenman J, Sharpe M, Xing L, Xia P, Lomax T, Low DA, Palta J (Apr 2004). "Implementing IMRT in clinical practice: a joint document of the American Society for Therapeutic Radiology and Oncology and the American Association of Physicists in Medicine". Int J Radiat Oncol Biol Phys. 58 (5): 1616–34. doi:10.1016/j.ijrobp.2003.12.008. PMID 15050343..</span></p></li><li id="quote_53"><span class="references-num">[53]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Intensity Modulated Radiation Therapy". Irsa.org. Retrieved 2012-04-20..</span></p></li><li id="quote_54"><span class="references-num">[54]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hall EJ, Wuu CS (2003). "Radiation-induced second cancers: the impact of 3D-CRT and IMRT". Int. J. Radiat. Oncol. Biol. Phys. 56 (1): 83–8. doi:10.1016/S0360-3016(03)00073-7. PMID 12694826..</span></p></li><li id="quote_55"><span class="references-num">[55]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Wing-Fai Loke; Tae-Young Choi; Teimour Maleki; Lech Papiez; Babak Ziaie; Byunghoo Jung (2010). "Magnetic Tracking System for Radiation Therapy". IEEE Transactions on Biomedical Circuits and Systems. 4 (4): 223–231. doi:10.1109/TBCAS.2010.2046737. PMID 23853368..</span></p></li><li id="quote_56"><span class="references-num">[56]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">M. Pourhomayoun; M. L. Fowler; Z. Jin. "A Novel Method for Tumor Localization and Tracking in Radiation Therapy". IEEE Asilomar Conference on Signals, Systems and Computers, 2012.</span></p></li><li id="quote_57"><span class="references-num">[57]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">M. Pourhomayoun; M. L. Fowler; Z. Jin. "Robustness Analysis of Sparsity Based Tumor Localization under Tissue Configuration Uncertainty". IEEE Signal Processing in Medicine and Biology Symposium (SPMB12), 2012.</span></p></li><li id="quote_58"><span class="references-num">[58]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A (Nov 2011). "Volumetric modulated arc therapy: a review of current literature and clinical use in practice". The British Journal of Radiology. 84 (1007): 967–96. doi:10.1259/bjr/22373346. PMC 3473700. PMID 22011829..</span></p></li><li id="quote_59"><span class="references-num">[59]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bertelsen A, Hansen CR, Johansen J, Brink C (May 2010). "Single Arc Volumetric modulated Arc therapy of head and neck cancer". Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology. 95 (2): 142–8. doi:10.1016/j.radonc.2010.01.011. PMID 20188427..</span></p></li><li id="quote_60"><span class="references-num">[60]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">VanGestel D, VanVliet-Vroegindeweij C, VanDenHeuvel F, Crijns W, Coelmont A, DeOst B, Holt A, Lamers E, Geussens Y, Nuyts S, VanDenWeyngaert D, VanDenWyngaert T, Vermorken JB, Gregoire V (Feb 2013). "RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison". Radiation Oncology. 8 (37). doi:10.1186/1748-717X-8-37..</span></p></li><li id="quote_61"><span class="references-num">[61]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Biegala M, Hydzik A (2016). "Analysis of dose distribution in organs at risk in patients with prostate cancer treated with the intensity-modulated radiation therapy and arc technique". Journal of Medical Physics. 41 (3): 198–204. doi:10.4103/0971-6203.189490. PMC 5019039..</span></p></li><li id="quote_62"><span class="references-num">[62]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Laurance, Jeremy (12 January 2009). "Brain tumor patient 'unaware' treatment was available on NHS". The Independent. Archived from the original on 22 June 2009. Retrieved 10 April 2009..</span></p></li><li id="quote_63"><span class="references-num">[63]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kereiakes JG, Rao DV; Rao (1992). "Auger electron dosimetry: report of AAPM Nuclear Medicine Committee Task Group No. 6". Med Phys. 19 (6): 1359. Bibcode:1992MedPh..19.1359K. doi:10.1118/1.596925. PMID 1461197..</span></p></li><li id="quote_64"><span class="references-num">[64]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Contact X-ray Brachytherapy for early rectal cancer". National Institute for Health and Care Excellence. September 2015..</span></p></li><li id="quote_65"><span class="references-num">[65]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Sun Myint A, Gerard J, Myerson RJ (2014). "Contact X-Ray Brachytherapy for Rectal Cancer". In Longo WE, Reddy V, Audisio RA. Modern Management of Cancer of the Rectum (in 英语). Springer. pp. 109ff. ISBN 9781447166092..</span></p></li><li id="quote_66"><span class="references-num">[66]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">American Association of Physicists in Medicine (February 2009). "The 2007 AAPM response to the CRCPD request for recommendations for the CRCPD's model regulations for electronic brachytherapy" (PDF). American Association of Physicists in Medicine. Retrieved 17 April 2010..</span></p></li><li id="quote_67"><span class="references-num">[67]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Gerbaulet A, et al. (2005). "Cervix carcinoma". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium: ACCO..</span></p></li><li id="quote_68"><span class="references-num">[68]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ash D, et al. (2005). "Prostate cancer". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium: ACCO..</span></p></li><li id="quote_69"><span class="references-num">[69]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Van Limbergen E, et al. (2005). "Breast cancer". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium: ACCO..</span></p></li><li id="quote_70"><span class="references-num">[70]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Van Limbergen E, et al. (2005). "Skin cancer". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium: ACCO..</span></p></li><li id="quote_71"><span class="references-num">[71]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Gerbaulet A, et al. (2005). "General aspects". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium: ACCO..</span></p></li><li id="quote_72"><span class="references-num">[72]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Stewart AJ; et al. (2007). "Radiobiological concepts for brachytherapy". In Devlin P. Brachytherapy. Applications and Techniques. Philadelphia: LWW..</span></p></li><li id="quote_73"><span class="references-num">[73]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Yashar CM, Blair S, Wallace A, Scanderbeg D (2009). "Initial clinical experience with the Strut-Adjusted Volume Implant brachytherapy applicator for accelerated partial breast irradiation". Brachytherapy. 8 (4): 367–72. doi:10.1016/j.brachy.2009.03.190. PMID 19744892..</span></p></li><li id="quote_74"><span class="references-num">[74]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Parker, Christopher (July 18, 2013). "Alpha Emiiter Radium-223 and Survival in Metastatic Prostate Cancer". New England Journal of Medicine. 369 (3): 213–23. doi:10.1056/NEJMoa1213755..</span></p></li><li id="quote_75"><span class="references-num">[75]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Sartor O (2004). "Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease". Rev Urol. 6 Suppl 10 (Suppl 10): S3–S12. PMC 1472939. PMID 16985930..</span></p></li><li id="quote_76"><span class="references-num">[76]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Fda批准首个治疗非霍奇金淋巴瘤的放射性药物产品 Archived 1月 19, 2009 at the Wayback Machine.</span></p></li><li id="quote_77"><span class="references-num">[77]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">托西托姆巴和碘I 131托西托姆巴-产品批准信息-许可行动 Archived 5月 13, 2009 at the Wayback Machine.</span></p></li><li id="quote_78"><span class="references-num">[78]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Dutta SW, Showalter SL, Showalter TN, Libby B, Trifiletti DM (April 2017). "Intraoperative radiation therapy for breast cancer patients: current perspectives". Breast Cancer. 9: 257–263. doi:10.2147/BCTT.S112516. PMC 5402914. PMID 28458578..</span></p></li><li id="quote_79"><span class="references-num">[79]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Belletti B, Vaidya JS, D'Andrea S, Entschladen F, Roncadin M, Lovat F, Berton S, Perin T, Candiani E, Reccanello S, Veronesi A, Canzonieri V, Trovò MG, Zaenker KS, Colombatti A, Baldassarre G, Massarut S (March 2008). "Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding". Clinical Cancer Research. 14 (5): 1325–32. doi:10.1158/1078-0432.CCR-07-4453. PMID 18316551..</span></p></li><li id="quote_80"><span class="references-num">[80]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hanley J, Debois MM, Mah D, Mageras GS, Raben A, Rosenzweig K, Mychalczak B, Schwartz LH, Gloeggler PJ, Lutz W, Ling CC, Leibel SA, Fuks Z, Kutcher GJ (October 1999). "Deep inspiration breath-hold technique for lung tumors: the potential value of target immobilization and reduced lung density in dose escalation". International Journal of Radiation Oncology, Biology, Physics. 45 (3): 603–11. doi:10.1016/S0360-3016(99)00154-6. PMID 10524412..</span></p></li><li id="quote_81"><span class="references-num">[81]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Deep Inspiration Breath-hold". Genesis Care. Retrieved 14 January 2016..</span></p></li><li id="quote_82"><span class="references-num">[82]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"University of Alabama at Birmingham Comprehensive Cancer Center, History of Radiation Oncology". Archived from the original (from the Wayback Machine) on 2008-01-05..</span></p></li><li id="quote_83"><span class="references-num">[83]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Pioneer in X-Ray Therapy". Science. New Series. 125 (3236): 18–19. 4 January 1957. Bibcode:1957Sci...125T..18.. doi:10.1126/science.125.3236.18. JSTOR 1752791..</span></p></li><li id="quote_84"><span class="references-num">[84]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"History of Radiation Therapy: The Evolution of Therapeutic Radiology". Rtanswers.com. 2010-03-31. Archived from the original on 2012-03-01. Retrieved 2012-04-20..</span></p></li><li id="quote_85"><span class="references-num">[85]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Closing in on cancer". The Economist. 16 September 2017. Retrieved 25 September 2017..</span></p></li></ul></div><div class="read-num">阅读 <!-- -->6062</div></div><div class="right-side" id="rightSide"><div class="side" id="lemma-side"><div class="side-title">版本记录</div><ul class="side-lst"><li><p class="side-lst-txt">暂无</p></li></ul><div class="user-card userCard"></div></div><div class="side"><div class="side-event"></div></div></div></div><div class="footer-box"><div id="footer"><div class="footer-logo-wrap"><div class="footer-logo"></div><div class="footer-logo-text">知识·传播·科普</div></div><div class="footer-info">本网站内容采用<a target="_blank" href="https://web.archive.org/web/20221028212143/https://creativecommons.org/licenses/by-sa/3.0/deed.zh?tdsourcetag=s_pctim_aiomsg">CC-BY-SA 3.0</a>授权</div><div class="footer-btn-wrap"><a target="_blank" href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/help/#user_protocol">用户协议</a><a target="_blank" href="https://web.archive.org/web/20221028212143/http://www.sogou.com/docs/terms.htm?v=1">免责声明</a><a target="_blank" href="https://web.archive.org/web/20221028212143/http://corp.sogou.com/private.html">隐私政策</a><a target="_blank" href="https://web.archive.org/web/20221028212143/https://baike.sogou.com/kexue/intro.htm">关于我们</a></div></div></div><script>window.lemmaInfo ={"lemmaId":"11137","versionId":"14996359232880906","title":"放射治疗","subtitle":"","abstracts":{"paragraphId":"14996359232880915","title":"简介","versionId":"14996359232880907","lemmaId":11137,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76052688,"name":"王一鑫","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576234526,"comment":null,"dependVersionId":0,"contentType":2,"content":"<p><b>放射治疗</b>或者<b>放射疗法</b>，通常缩写作<b>RT</b>，<b>RTx</b>或<b>XRT</b>，是一种使用电离辐射的疗法，通常作为癌症治疗的一部分，用于控制或杀死恶性肿瘤细胞，一般由线性加速器输送。如果作用于身体的某个区域，放射治疗或对多种癌症具有疗效。它也可以作为辅助治疗的一部分，以防止原发性恶性肿瘤（例如，早期乳腺癌）在切除手术后复发。放射疗法与化疗具有协同作用，在易感癌症的化疗前、中和后期都有使用。肿瘤学中与放射治疗相关的分支学科叫做<b>放射肿瘤学</b>。 </p>\n<p>放射疗法通常应用于癌性肿瘤，因为它能够控制细胞生长。电离辐射通过破坏癌组织的脱氧核糖核酸，导致细胞死亡而起作用。为了避开正常组织（辐射必须穿过皮肤、器官等来治疗肿瘤），成形的辐射束从几个暴露角度瞄准，在肿瘤处相交，从而提供远大于周围健康组织的吸收剂量。除了肿瘤本身之外，如果引流淋巴结在临床或放射学上与肿瘤有关，或者存在亚临床恶性扩散的风险，则辐射场也可能覆盖引流淋巴结。考虑到日常变化和肿瘤内部运动的不确定性，肿瘤周围的正常组织边缘也需要覆盖。这些不确定性可能由内部运动（例如，呼吸和膀胱充盈）和外部皮肤标记相对于肿瘤位置的运动引起。 </p>\n<p>放射肿瘤学是与放射处方有关的医学专业，不同于放射学，即放射在医学成像和诊断中的使用。放射疗法通常由放射肿瘤学家经处方给出，目的是治愈（“有疗效”）或作为辅助治疗。放射肿瘤学也可以用作姑息疗法（在不可能治愈并且以局部疾病控制或症状缓解为目的的情况下）或者作为治疗疗法（在该疗法具有生存益处并且有疗效的情况下）。放射疗法联合外科、化学疗法、激素疗法、免疫疗法，或与该四者重的几种联合的疗法也很常见。在某种程度上，大多数常见的癌症都可以用放射疗法治疗。 </p>\n<p>具体治疗意图（治愈、辅助治疗、新辅助治疗、或姑息疗法）将取决于肿瘤类型、位置和分期以及患者的总体健康状况。全身照射（TBI）是一种骨髓移植前预处理的放射治疗技术。短距离放射治疗，即放射源放置在需要治疗的区域内或附近，是另一种形式的放射治疗，其能使健康组织在乳腺癌、前列腺癌和其他器官癌症手术过程中暴露最小化。放射疗法可以应用于几种非恶性疾病治疗，例如三叉神经痛、听神经瘤、严重甲状腺眼病、翼状胬肉、色素沉着绒毛结节性滑膜炎，也可以预防瘢痕增生，血管再狭窄，和异位骨化。限制放射疗法对于非恶性疾病治疗的部分原因在于辐射存在诱发癌症的风险。 </p>","pics":null,"card":null,"references":[],"versionCount":0},"card":{"paragraphId":"14996359232880916","title":"基本信息","versionId":"14996359232880908","lemmaId":0,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76052688,"name":"王一鑫","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576234526,"comment":null,"dependVersionId":0,"contentType":3,"content":"","pics":null,"card":{"cardItems":[{"key":"ICD-10-PCS","value":"D"},{"key":"ICD-9-CM","value":"92.2-92.3"},{"key":"MeSH","value":"D011878"},{"key":"OPS-301","value":"8–52"},{"key":"MedlinePlus","value":"001918"}]},"references":[],"versionCount":0},"categories":[{"id":13,"name":"药学","parents":[]}],"creator":{"uid":76052688,"name":"王一鑫","pic":"https://web.archive.org/web/20221028212143/https://cache.soso.com/qlogo/g?b=oidb&k=J98zKlez9iaWgwHsRmHmYicA&s=100&t=1555573700","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":157,"partnerIdCreateTime":1595844884,"partnerIdPoped":false},"createTime":1571038632,"editor":{"uid":76052688,"name":"王一鑫","pic":"https://web.archive.org/web/20221028212143/https://cache.soso.com/qlogo/g?b=oidb&k=J98zKlez9iaWgwHsRmHmYicA&s=100&t=1555573700","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":157,"partnerIdCreateTime":1595844884,"partnerIdPoped":false},"editTime":1576234526,"state":1,"versionCount":1,"upNum":0,"downNum":0,"pics":[{"originalUrl":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16722?w=300&h=117&titlename=%E5%AF%B9%E4%B8%80%E5%90%8D%E6%82%A3%E6%9C%89%E5%BC%A5%E6%BC%AB%E6%80%A7%E8%84%91%E6%A1%A5%E5%86%85%E7%A5%9E%E7%BB%8F%E8%83%B6%E8%B4%A8%E7%98%A4%E7%9A%84%E6%82%A3%E8%80%85%E8%BF%9B%E8%A1%8C%E6%94%BE%E5%B0%84%E6%B2%BB%E7%96%97%EF%BC%8C%E6%94%BE%E5%B0%84%E5%89%82%E9%87%8F%E7%94%A8%E5%BD%A9%E8%89%B2%E7%BC%96%E7%A0%81%E3%80%82","url":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16722","rw":300,"rh":117,"title":"对一名患有弥漫性脑桥内神经胶质瘤的患者进行放射治疗，放射剂量用彩色编码。","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16724?w=300&h=331&titlename=%E6%89%8B%E8%A1%A8%E9%9D%A2%E6%94%BE%E5%B0%84%E6%B2%BB%E7%96%97%E5%85%A5%E5%8F%A3%E7%9A%84%E5%B0%84%E6%9D%9F%E7%9C%BC%E8%A7%86%E5%9B%BE%EF%BC%8C%E5%85%B6%E4%B8%AD%E5%BC%95%E7%BA%BF%E5%B1%8F%E8%94%BD%E5%88%87%E5%8F%A3%E6%94%BE%E7%BD%AE%E5%9C%A8%E6%9C%BA%E5%99%A8%E6%9C%BA%E6%9E%B6%E4%B8%AD","url":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16724","rw":300,"rh":331,"title":"手表面放射治疗入口的射束眼视图，其中引线屏蔽切口放置在机器机架中","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16727?w=213&h=258&titlename=%E4%B8%80%E7%A7%8D%E8%BF%9C%E7%A8%8B%E6%B2%BB%E7%96%97%E8%BE%90%E5%B0%84%E8%83%B6%E5%9B%8A%EF%BC%8C%E7%94%B1%E4%BB%A5%E4%B8%8B%E7%89%A9%E8%B4%A8%E7%BB%84%E6%88%90%EF%BC%9A%20%E4%B8%80%E4%B8%AA%20%E7%AC%A6%E5%90%88%E5%9B%BD%E9%99%85%E6%A0%87%E5%87%86%E7%9A%84%E6%94%BE%E5%B0%84%E6%BA%90%E5%AE%B9%E5%99%A8%20%EF%BC%88%E9%80%9A%E5%B8%B8%E4%B8%BA%E9%93%85%E5%88%B6%E5%93%81%EF%BC%89%EF%BC%8C%20%E4%B8%80%E4%B8%AA%E6%89%A3%E7%8E%AF%20%E4%B8%80%E4%B8%AA%E8%BF%9C%E7%A8%8B%E6%B2%BB%E7%96%97%20%E2%80%9D%E6%BA%90%E2%80%9C%EF%BC%8C%20%E5%8C%85%E6%8B%AC%20%E7%84%8A%E6%8E%A5%E5%9C%A8%E4%B8%80%E8%B5%B7%E7%9A%84%E4%B8%A4%E4%B8%AA%E5%B5%8C%E5%A5%97%E4%B8%8D%E9%94%88%E9%92%A2%E7%BD%90%EF%BC%8C%20%E4%B8%8A%E4%B8%8B%E5%90%84%E6%9C%89%E4%B8%80%E4%B8%AA%E4%B8%8D%E9%94%88%E9%92%A2%E7%9B%96%E5%AD%90%EF%BC%8C%E5%8C%85%E8%A3%B9%20%E4%B8%80%E4%B8%AA%E9%98%B2%E6%8A%A4%E6%80%A7%E5%B1%8F%E9%9A%9C%EF%BC%88%E9%80%9A%E5%B8%B8%E7%94%B1%E9%93%80%E6%88%96%E9%92%A8%E5%90%88%E9%87%91%E5%88%B6%E6%88%90%EF%BC%89%EF%BC%8C%20%E4%BB%A5%E5%8F%8A%E4%B8%80%E4%B8%AA%E8%A3%85%E6%9C%89%E6%94%BE%E5%B0%84%E6%BA%90%E7%9A%84%E5%9C%86%E6%9F%B1%E4%BD%93%EF%BC%8C%E9%80%9A%E5%B8%B8%E6%98%AF%20%E9%92%B4-60%E3%80%82%E2%80%9C%E6%94%BE%E5%B0%84%E6%BA%90%E2%80%9D%E7%9A%84%E7%9B%B4%E5%BE%84%E9%80%9A%E5%B8%B8%E4%B8%BA%2030%20mm.","url":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16727","rw":213,"rh":258,"title":"一种远程治疗辐射胶囊，由以下物质组成： 一个 符合国际标准的放射源容器 （通常为铅制品）， 一个扣环 一个远程治疗 ”源“， 包括 焊接在一起的两个嵌套不锈钢罐， 上下各有一个不锈钢盖子，包裹 一个防护性屏障（通常由铀或钨合金制成）， 以及一个装有放射源的圆柱体，通常是 钴-60。“放射源”的直径通常为 30 mm.","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028212143/https://img03.sogoucdn.com/app/a/200698/sogou_science_16729?w=300&h=225&titlename=%E7%93%A6%E9%87%8C%E5%AE%89%20TruBeam%20%E7%9B%B4%E7%BA%BF%E5%8A%A0%E9%80%9F%E5%99%A8%EF%BC%8C%E7%94%A8%E4%BA%8E%E8%BE%93%E9%80%81IMRT","url":"https://web.archive.org/web/20221028212143/https://img03.sogoucdn.com/app/a/200698/sogou_science_16729","rw":300,"rh":225,"title":"瓦里安 TruBeam 直线加速器，用于输送IMRT","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028212143/https://img04.sogoucdn.com/app/a/200698/sogou_science_16731?w=300&h=225&titlename=SAVI%E8%BF%91%E8%B7%9D%E7%A6%BB%E6%94%BE%E5%B0%84%E6%B2%BB%E7%96%97%E8%AE%BE%E5%A4%87","url":"https://web.archive.org/web/20221028212143/https://img04.sogoucdn.com/app/a/200698/sogou_science_16731","rw":300,"rh":225,"title":"SAVI近距离放射治疗设备","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028212143/https://img03.sogoucdn.com/app/a/200698/sogou_science_16732?w=420&h=343&titlename=1910%E5%B9%B4%E8%82%BA%E7%BB%93%E6%A0%B8%E7%9A%84x%E7%BA%BF%E6%B2%BB%E7%96%97%E3%80%82%E5%9C%A820%E4%B8%96%E7%BA%AA20%E5%B9%B4%E4%BB%A3%E4%B9%8B%E5%89%8D%EF%BC%8C%E4%BA%BA%E4%BB%AC%E8%BF%98%E4%B8%8D%E4%BA%86%E8%A7%A3%E8%BE%90%E5%B0%84%E7%9A%84%E5%8D%B1%E5%AE%B3%EF%BC%8C%E5%AE%83%E8%A2%AB%E7%94%A8%E6%9D%A5%E6%B2%BB%E7%96%97%E5%90%84%E7%A7%8D%E7%96%BE%E7%97%85%E3%80%82","url":"https://web.archive.org/web/20221028212143/https://img03.sogoucdn.com/app/a/200698/sogou_science_16732","rw":420,"rh":343,"title":"1910年肺结核的x线治疗。在20世纪20年代之前，人们还不了解辐射的危害，它被用来治疗各种疾病。","alt":null,"width":0,"height":0}],"catalogs":[{"level":1,"title":"医疗用途","paragraphId":"14996359249658116","subCatalogs":null},{"level":1,"title":"副作用","paragraphId":"14996359249658117","subCatalogs":[{"level":2,"title":"急性副作用","paragraphId":"14996359249658117","subCatalogs":null},{"level":2,"title":"晚期副作用","paragraphId":"14996359249658117","subCatalogs":null},{"level":2,"title":"累积副作用","paragraphId":"14996359249658117","subCatalogs":null},{"level":2,"title":"对生殖的影响","paragraphId":"14996359249658117","subCatalogs":null},{"level":2,"title":"对垂体系统的影响","paragraphId":"14996359249658117","subCatalogs":null},{"level":2,"title":"放射治疗事故","paragraphId":"14996359249658117","subCatalogs":null}]},{"level":1,"title":"用于非癌症疾病","paragraphId":"14996359249658118","subCatalogs":null},{"level":1,"title":"技术","paragraphId":"14996359249658119","subCatalogs":[{"level":2,"title":"作用机理","paragraphId":"14996359249658119","subCatalogs":null},{"level":2,"title":"剂量","paragraphId":"14996359249658119","subCatalogs":null}]},{"level":1,"title":"类型","paragraphId":"14996359266435337","subCatalogs":[{"level":2,"title":"外束放射疗法","paragraphId":"14996359266435337","subCatalogs":null},{"level":2,"title":"接触式X射线近距离放射疗法","paragraphId":"14996359266435337","subCatalogs":null},{"level":2,"title":"近距离放射疗法（密封源放射疗法）","paragraphId":"14996359266435337","subCatalogs":null},{"level":2,"title":"非密封源放射疗法（全身放射性同位素疗法）","paragraphId":"14996359266435337","subCatalogs":null},{"level":2,"title":"术中放疗","paragraphId":"14996359266435337","subCatalogs":null},{"level":2,"title":"深吸屏气","paragraphId":"14996359266435337","subCatalogs":null}]},{"level":1,"title":"历史","paragraphId":"14996359266435338","subCatalogs":null},{"level":1,"title":"参考文献","paragraphId":"-1","subCatalogs":null}],"paragraphs":[{"paragraphId":"14996359249658116","title":"医疗用途","versionId":"14996359232880909","lemmaId":11137,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76052688,"name":"王一鑫","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576234526,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p></p><p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"117\" img_width=\"300\" titlename=\"对一名患有弥漫性脑桥内神经胶质瘤的患者进行放射治疗，放射剂量用彩色编码。\" data-src=\"https://img02.sogoucdn.com/app/a/200698/sogou_science_16722\"> </p><p></p> \n<p>不同的癌症对放射疗法有不同的反应。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup><sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup><sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup> </p>\n<p>癌症对辐射的反应可用其辐射敏感性来描述。中等剂量的辐射会迅速杀死对辐射高度敏感的癌细胞，包括白血病、大多数淋巴瘤和生殖细胞肿瘤。大多数上皮癌放射敏感性不高，故而需要更高的放射剂量（60-70Gy）才能实现根治。某些类型的癌症具有明显的抗辐射能力，也就是说，所需剂量可能要远高于临床实践中的安全剂量，才能产生根治效果。肾细胞癌和黑素瘤通常被认为是抗辐射的，但对于许多转移性黑色素瘤患者而言，放射治疗仍然是一种姑息疗法。放射疗法联合免疫疗法的相关研究众多，且对于黑色素瘤和其他癌症的治疗展现出了一定前景。<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup> </p>\n<p>在实际临床实践中，区分特定肿瘤的放射敏感性（在某种意义上可以看作一项实验室检查）和癌症的放射“可治愈性”是很重要的。例如，白血病通常不能用放射疗法治愈，因为它们在全身各处均有散播。淋巴瘤如果局限于身体的一个区域，则可能是可以根治的。同样，许多常见的中度放射性反应肿瘤如果处于早期阶段，通常会接受治疗剂量的放射治疗。例如：非黑色素瘤皮肤癌、头颈癌、乳腺癌、非小细胞肺癌、宫颈癌、肛门癌和前列腺癌。转移性癌症通常无法用放射疗法治愈，因为不可能进行全身放疗。 </p>\n<p>治疗前，通常会进行CT扫描以识别肿瘤和周围正常结构，并在患者体表绘制小的皮肤标记来引导治疗区域。<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup>在这个阶段，病人的体位是至关重要的，因为在治疗过程中，病人必须被设置在相同的体位。为此，目前已开发了许多患者定位装置，包括可以固定患者体位的面罩和垫子。 </p>\n<p>肿瘤对放射治疗的反应也与其大小有关。由于复杂的放射生物学，体积较大的肿瘤对辐射的反应弱于较小的肿瘤或镜检病变。为克服这种影响，有各种应对的治疗策略。最常见的一种是放射治疗前的手术切除。这在乳腺癌的治疗中最常见，广泛局部切除或乳房切除术，随后再行辅助放疗。另一种方法是在根治性放疗前用辅助放疗缩小肿瘤。第三种技术是通过在放射治疗过程中给予某些药物来提高癌症的放射敏感性。放射增敏药物包括：顺铂、尼莫唑和西妥昔单抗等。 </p>\n<p>放射治疗的效果因不同类型的癌症和不同群体而异。<sup><a href=\"#quote_6\" class=\"kx_ref\">[6]</a></sup>例如，对于保乳手术后的乳腺癌，已经发现放射治疗可将疾病复发率减半。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16722?w=300&h=117&titlename=%E5%AF%B9%E4%B8%80%E5%90%8D%E6%82%A3%E6%9C%89%E5%BC%A5%E6%BC%AB%E6%80%A7%E8%84%91%E6%A1%A5%E5%86%85%E7%A5%9E%E7%BB%8F%E8%83%B6%E8%B4%A8%E7%98%A4%E7%9A%84%E6%82%A3%E8%80%85%E8%BF%9B%E8%A1%8C%E6%94%BE%E5%B0%84%E6%B2%BB%E7%96%97%EF%BC%8C%E6%94%BE%E5%B0%84%E5%89%82%E9%87%8F%E7%94%A8%E5%BD%A9%E8%89%B2%E7%BC%96%E7%A0%81%E3%80%82","url":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16722","rw":300,"rh":117,"title":"对一名患有弥漫性脑桥内神经胶质瘤的患者进行放射治疗，放射剂量用彩色编码。","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"14996359249658117","title":"副作用","versionId":"14996359232880910","lemmaId":11137,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76052688,"name":"王一鑫","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576234526,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>放射疗法本身没有痛苦。许多低剂量的姑息疗法（例如，对骨转移瘤的放射疗法）仅产生微小副作用，甚至没有副作用。但由于治疗区域内的水肿压迫神经，在治疗后的几天内可能会出现短期疼痛发作。较高剂量可在治疗期间（急性副作用）、治疗后数月或数年（长期副作用）或再治疗后（累积副作用）导致不同的副作用。副作用的性质、严重程度和持续时间取决于接受辐射的器官、治疗本身（辐射类型、剂量、分级、同步化疗）和患者。 </p>\n<p>大多数副作用是可以预测且在预料之中的。辐射的副作用通常局限于患者身体接受治疗的部位。且副作用是剂量依赖性的；例如，较高剂量的头颈部辐射可能与心血管并发症、甲状腺功能障碍和垂体轴功能障碍有关。<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup>现代放射疗法旨在将副作用降至最低，并帮助患者理解和应对不可避免的副作用。 </p>\n<p>目前已有报告的主要副作用是疲劳和皮肤刺激，如轻度至中度的灼伤。疲劳通常发生在治疗过程的中间，在治疗结束后会持续数周。受刺激的皮肤会愈合，但可能不会像以前那样有弹性。<sup><a href=\"#quote_9\" class=\"kx_ref\">[9]</a></sup> </p> \n<h3>急性副作用</h3> \n<dl>\n <dt>\n  恶心和呕吐\n </dt> \n <dd>\n  这并非放射治疗的常见副作用，并且在机理上仅与胃或腹部的治疗（其通常在治疗后几小时发生反应）相关，或者与在治疗某些头颈部肿瘤期间对头部中某些产生恶心感的结构的放射治疗相关，最常见的是内耳的前庭。\n  <sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup>和任何其他导致痛苦的治疗一样，有些患者在放疗期间会立即呕吐，或者是有想要呕吐的感觉，但这被认为是一种心理反应。任何原因的恶心都可以用止吐药来治疗。\n  <sup><a href=\"#quote_11\" class=\"kx_ref\">[11]</a></sup>\n </dd> \n <dt>\n  对上皮表面的损伤\n  <sup><a href=\"#quote_12\" class=\"kx_ref\">[12]</a></sup>\n </dt> \n <dd>\n  上皮表面可能因放射治疗而受损。根据治疗区域，可能包括皮肤、口腔粘膜、咽、肠粘膜和输尿管。损伤的发生率和恢复率取决于上皮细胞的周转率。通常情况下，治疗几周后皮肤将开始呈现粉红色，并伴随疼痛。在治疗期间以及放射治疗结束后的一周内，反应可能会变得更加严重，皮肤可能会破裂。虽然这种湿性脱皮令人不适，但通常恢复很快。皮肤反应往往在皮肤有自然褶皱的区域更严重，例如女性乳房下、耳后和腹股沟。\n </dd> \n <dt>\n  口腔、喉咙和胃部疼痛\n </dt> \n <dd>\n  如果头部和颈部接受放疗，口腔和喉咙通常会出现暂时性疼痛和溃疡。\n  <sup><a href=\"#quote_13\" class=\"kx_ref\">[13]</a></sup>若病情严重，可能会影响吞咽，患者可能需要止痛药和营养支持/食物补充剂。如果直接治疗食道，或者更为常见的一种情况是在肺癌治疗过程中接受一定剂量的附带辐射，也会引发食道疼痛。当治疗肝脏恶性肿瘤和转移时，侧支辐射可能导致胃、胃或十二指肠壅积症\n  <sup><a href=\"#quote_14\" class=\"kx_ref\">[14]</a></sup>\n  <sup><a href=\"#quote_15\" class=\"kx_ref\">[15]</a></sup>这种附带辐射通常是由正在输注的放射性试剂的非靶向输送（回流）引起的。\n  <sup><a href=\"#quote_16\" class=\"kx_ref\">[16]</a></sup>可以使用放射技巧、技术和装置来降低这种不良副作用的发生。\n  <sup><a href=\"#quote_17\" class=\"kx_ref\">[17]</a></sup>\n </dd> \n <dt>\n  肠道不适\n </dt> \n <dd>\n  下肠道若直接接受放射治疗（直肠或肛门癌的治疗），或通过放射治疗暴露于其他骨盆结构（前列腺、膀胱、女性生殖道），可出现疼痛、腹泻和恶心等典型症状。\n </dd> \n <dt>\n  肿胀\n </dt> \n <dd>\n  作为一般炎症的一部分，软组织肿胀可能会在放射治疗中引起问题。在脑肿瘤和脑转移瘤治疗过程中尤其，特别是在尤其是在既存颅内压升高或肿瘤引起管腔几乎完全阻塞（例如气管或主支气管）的情况下。放射治疗之前可考虑手术干预。如果认为手术不必要或不适当，患者可在放射治疗期间接受类固醇治疗，以减少肿胀。\n </dd> \n <dt>\n  不孕不育\n </dt> \n <dd>\n  性腺（卵巢和睾丸）对辐射非常敏感。直接暴露于大多数正常治疗剂量的辐射后，它们可能无法产生配子。如果性腺不是主要治疗区域，则所有身体部位的治疗计划都应最大限度地减少（若无法完全排除）性腺的剂量。\n </dd>\n</dl> \n<h3>晚期副作用</h3> \n<p>晚期副作用发生在治疗后几个月到几年，且一般局限于治疗区域。通常是由血管和结缔组织细胞的损伤引起的。通过将治疗分散化，可以明显减少晚期副作用。 </p> \n<dl>\n <dt>\n  纤维化\n </dt> \n <dd>\n  由于扩散结疤过程，经过辐照的组织随着时间的推移，其弹性往往会降低。\n </dd> \n <dt>\n  毛发脱落\n </dt> \n <dd>\n  接受辐射剂量超过1 Gy的任何有毛发的皮肤都可能发生脱毛（脱发）。该种副作用仅发生在辐射场中。10 Gy单剂量导致的脱发可能是永久性的 ，但如果分次治疗，在剂量超过45 Gy之前，可能不会发生永久性脱发。\n </dd> \n <dt>\n  干燥\n </dt> \n <dd>\n  唾液腺和泪腺的辐射耐受性约为30 Gy（2 Gy每次），这一剂量已经超过了大多数性头颈癌根治治疗所需的剂量。口干（口腔干燥）和眼睛干涩（干眼症）可能成为令人烦恼的长期问题，并严重降低患者的生存质量。同样，进行放疗后的皮肤（例如腋窝）的汗腺往往会失去作用，原本潮湿的阴道粘膜经骨盆照射后常会变得干燥。\n </dd> \n <dt>\n  淋巴水肿\n </dt> \n <dd>\n  淋巴水肿是一种局部液体滞留和组织肿胀的症状，可能是放射治疗期间淋巴系统持续受损造成的。这是乳腺癌放疗患者在手术后接受辅助腋窝放疗以清除腋窝淋巴结时最常报告的并发症。\n  <sup><a href=\"#quote_18\" class=\"kx_ref\">[18]</a></sup>\n </dd> \n <dt>\n  癌症\n </dt> \n <dd>\n  辐射是癌症的潜在原因，在极少数患者中可见继发性恶性肿瘤——通常不到1/1000。它通常发生在治疗后20-30年，尽管一些血液系统恶性肿瘤可能在5-10年内发展。在绝大多数情况下，这种风险要远远低于原发性癌症所带来的风险。作为副作用发生的癌症一般局限于患者接受治疗的区域。\n </dd> \n <dt>\n  心血管疾病\n </dt> \n <dd>\n  据既往乳腺癌放疗方案观察，辐射会增加心脏病和死亡的风险。\n  <sup><a href=\"#quote_19\" class=\"kx_ref\">[19]</a></sup>治疗性辐射将后续心血管事件（即心脏病发作或中风）的风险增加到正常人的1.5至4倍（包括加重因素）。\n  <sup><a href=\"#quote_20\" class=\"kx_ref\">[20]</a></sup>这种增加取决于剂量，也与放射治疗的剂量强度、体积和位置有关。\n </dd> \n <dd>\n  心血管晚期副作用被称为辐射诱发心脏病（RIHD）和辐射诱发血管疾病（RIVD）。\n  <sup><a href=\"#quote_21\" class=\"kx_ref\">[21]</a></sup>其症状是剂量依赖性的，包括心肌病、心肌纤维化、瓣膜性心脏病、冠状动脉疾病、异常心脏节律和外周动脉疾病。辐射诱导的纤维化、血管细胞损伤和氧化应激可导致上述和其他晚期副作用症状。\n  <sup><a href=\"#quote_21\" class=\"kx_ref\">[21]</a></sup>大多数辐射诱发的心血管疾病发生在治疗后10年或以后，使得因果关系的确定更加困难。\n  <sup><a href=\"#quote_20\" class=\"kx_ref\">[20]</a></sup>\n </dd> \n <dt>\n  认知能力下降\n </dt> \n <dd>\n  在对头部进行放射治疗可能会导致认知能力下降。这一副作用在5至11岁的幼儿中尤为明显。例如，已有研究发现，5岁儿童的智商在治疗后每年下降几个智商点。\n  <sup><a href=\"#quote_22\" class=\"kx_ref\">[22]</a></sup>\n </dd> \n <dt>\n  放射性肠道病\n </dt> \n <dd>\n  腹部和骨盆放射治疗后，胃肠道可能受损。\n  <sup><a href=\"#quote_23\" class=\"kx_ref\">[23]</a></sup>萎缩、纤维化和血管变化产生吸收不良、腹泻、脂肪泻、出血，其中胆汁酸腹泻和维生素B12 吸收不良通常是由于回肠受累引起的。骨盆辐射疾病包括放射性直肠炎，导致出血、腹泻和尿急，\n  <sup><a href=\"#quote_24\" class=\"kx_ref\">[24]</a></sup>当膀胱受到影响时也可能引起放射性膀胱炎。\n </dd> \n <dt>\n  辐射诱发的多发性神经病\n </dt> \n <dd>\n  尽管放射治疗至关重要，但也可能损伤目标区域附近或输送路径内的神经，因为神经组织也对放射线敏感。\n  <sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup>电离辐射引起的神经损伤分阶段发生，初始阶段为微血管损伤、毛细血管损伤和神经脱髓鞘。\n  <sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup>随后的损伤包括血管收缩和神经压迫，这是由于辐射引起的不受控制的纤维组织生长。\n  <sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup>辐射诱发的多发性神经病，ICD-10-CM代码G62.82 ，发生在大约1-5%接受放射治疗的患者中。\n  <sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup>\n  <sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup>\n </dd> \n <dd>\n  根据照射区域的不同，后效应神经病变可能发生在中枢神经系统或周围神经系统。例如，在中枢神经系统中，颅神经损伤通常表现为发生在治疗后1-14年的视力丧失。\n  <sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup>在PNS中，丛神经损伤表现为放射诱导的臂神经丛病变或放射诱导的腰骶神经丛病变，可在治疗后30年内出现。\n  <sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup>\n </dd>\n</dl> \n<h3>累积副作用</h3> \n<p>不应将放疗产生的累积效应与长期效应混淆——当短期效应消失，长期效应为亚临床效应时，再辐射仍可能存在问题。<sup><a href=\"#quote_27\" class=\"kx_ref\">[27]</a></sup>这些剂量由放射肿瘤学家计算，在随后的放射发生之前，要考虑许多因素。 </p> \n<h3>对生殖的影响</h3> \n<p>受孕后两周内的放射疗法对于受精卵是致命的，但不会产生畸形。<sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup>怀孕期间高剂量辐射会导致胎儿先天异常、生长受损和智力残疾，并且后代患儿童白血病和其他肿瘤的风险可能会增加。<sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup> </p>\n<p>在既往接受过放射治疗的男性中，治疗后配偶所生子女的遗传缺陷或先天性畸形似乎没有增加。<sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup>然而，使用辅助生殖技术和显微操作技术可能会增加这种风险。<sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup> </p> \n<h3>对垂体系统的影响</h3> \n<p>垂体机能减退通常出现在鞍区和鞍旁肿瘤、鞍外脑肿瘤、头颈部肿瘤的放射治疗后以及全身性恶性肿瘤的放射治疗后。<sup><a href=\"#quote_29\" class=\"kx_ref\">[29]</a></sup>辐射诱导的垂体机能减退主要影响生长激素和性腺激素<sup><a href=\"#quote_29\" class=\"kx_ref\">[29]</a></sup>的分泌。相比之下，促肾上腺皮质激素 （ACTH）和促甲状腺激素 （TSH）缺乏在辐射诱发的垂体机能减退中比较少见。<sup><a href=\"#quote_29\" class=\"kx_ref\">[29]</a></sup>催乳素分泌的变化通常是轻微的，化疗后加压素缺乏则非常罕见。<sup><a href=\"#quote_29\" class=\"kx_ref\">[29]</a></sup> </p> \n<h3>放射治疗事故</h3> \n<p>一般有严格的程序来减少患者意外过度暴露于辐射的风险。然而，偶尔还是会有意外发生；例如，放射治疗机 Therac-25在1985年至1987年期间至少造成了六起事故，在这些事故中，患者被给予的剂量是预期剂量的一百倍；辐射过量直接导致两人死亡。从2005年到2010年，密苏里的一家医院在五年内造成了76名患者过度暴露（大多数是脑癌患者），原因是新的放射设备安装不正确。<sup><a href=\"#quote_30\" class=\"kx_ref\">[30]</a></sup> </p>\n<p>放射肿瘤学家、医学物理学家和放射治疗团队的其他成员正在努力消除这些罕见的医疗错误。ASTRO发起了一项名为“安全定位”的安全倡议，旨在记录全国范围内的错误，以便医生能够从每一例医疗错误中吸取教训，并防止其再次发生。ASTRO还发布了一个问题列表，供患者向医生询问辐射安全问题，以确保每种治疗尽可能安全。<sup><a href=\"#quote_31\" class=\"kx_ref\">[31]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14996359249658118","title":"用于非癌症疾病","versionId":"14996359232880911","lemmaId":11137,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76052688,"name":"王一鑫","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576234526,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p></p><p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"331\" img_width=\"300\" titlename=\"手表面放射治疗入口的射束眼视图，其中引线屏蔽切口放置在机器机架中\" data-src=\"https://img02.sogoucdn.com/app/a/200698/sogou_science_16724\"> </p><p></p> \n<p>放射疗法可用于治疗早期的杜普伊特伦病和莱德尔软管病。当杜普伊特伦氏病处于结节和索状阶段或手指处于小于10度的最小变形阶段时，考虑使用放射治疗来防止疾病的进一步发展。在某些情况下，术后也使用放射疗法来防止疾病继续发展。低剂量辐射通常使用三戈瑞的辐射五天，休息三个月，再接受三戈瑞的辐射五天。<sup><a href=\"#quote_32\" class=\"kx_ref\">[32]</a></sup> </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16724?w=300&h=331&titlename=%E6%89%8B%E8%A1%A8%E9%9D%A2%E6%94%BE%E5%B0%84%E6%B2%BB%E7%96%97%E5%85%A5%E5%8F%A3%E7%9A%84%E5%B0%84%E6%9D%9F%E7%9C%BC%E8%A7%86%E5%9B%BE%EF%BC%8C%E5%85%B6%E4%B8%AD%E5%BC%95%E7%BA%BF%E5%B1%8F%E8%94%BD%E5%88%87%E5%8F%A3%E6%94%BE%E7%BD%AE%E5%9C%A8%E6%9C%BA%E5%99%A8%E6%9C%BA%E6%9E%B6%E4%B8%AD","url":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16724","rw":300,"rh":331,"title":"手表面放射治疗入口的射束眼视图，其中引线屏蔽切口放置在机器机架中","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"14996359249658119","title":"技术","versionId":"14996359232880912","lemmaId":11137,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76052688,"name":"王一鑫","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576234526,"comment":null,"dependVersionId":0,"contentType":1,"content":"<h3>作用机理</h3> \n<p>放射疗法通过破坏癌细胞的脱氧核糖核酸发挥作用。这种DNA损伤是由光子或带电粒子这两种能量之一引起的。其可以对组成DNA链的原子产生直接或间接电离。间接电离是水电离的结果，可形成自由基，特别是羟基，然后破坏DNA。 </p>\n<p>在光子治疗中，大多数辐射效应是通过自由基产生的。细胞具有修复单链和双链DNA 损伤的机制。其中双链DNA断裂更难修复，并可能导致显著的染色体异常和遗传缺失。靶向双链断裂增加了细胞死亡的可能性。癌细胞通常不太分化，更像是干细胞；它们比大多数健康的分化细胞繁殖更加旺盛，并且修复亚致死损伤的能力降低。单链DNA损伤可通过细胞分裂传递，而且癌细胞DNA的损伤会累积，导致细胞死亡或减缓其繁殖。 </p>\n<p>光子放射治疗的一个主要限制是实体肿瘤细胞缺乏氧气。实体肿瘤的生长可能会超过其血液供应，从而处于低氧状态，称为缺氧。氧是一种强有力的放射增敏剂，通过形成破坏DNA的自由基来提高给定剂量辐射的有效性。缺氧环境中的肿瘤细胞对辐射损伤的抵抗力可能是正常氧气环境中的2到3倍。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup>许多研究致力于克服缺氧这一问题，包括使用高压氧气瓶、热疗（将血管扩张到肿瘤部位）、增氧后的血液替代品、低氧细胞放射增敏剂药物如米索尼达唑和甲硝唑以及低氧细胞毒素（组织毒素），如地拉帕胺。正在研究的新方法包括对使用氧扩散增强化合物，如反式西红花酸钠 （TSC）作为放射增敏剂，目前已进入临床前和临床研究阶段。<sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup> </p>\n<p>带电粒子如质子和硼、碳和氖离子可以通过高LET （ 传能线密度）对癌细胞DNA造成直接损伤，并且具有独立于肿瘤氧供应的抗肿瘤效果，因为这些粒子主要通过直接能量转移发挥作用，通常可导致双链DNA断裂。由于质子和其他带电粒子的质量相对较大，它们在组织中的侧向散射很小（电子束不会扩展太多），从而可以聚焦在肿瘤形状上，仅向周围组织传递小剂量的副作用。利用布拉格尖峰效应，还可以使它们更精确地靶向肿瘤。关于IMRT高精度放射线疗法（IMRT）与带电粒子疗法的不同效果，请参见质子疗法。该程序减少了带电粒子辐射源治疗肿瘤时对健康组织的损伤，并限定了到达肿瘤后的组织损伤范围。相比之下，IMRT使用不带电荷的粒子导致其能量在离开身体时可能损害健康细胞。这种损伤不是治疗性的，会增加治疗副作用，并增加继发性癌症诱发的可能性。<sup><a href=\"#quote_35\" class=\"kx_ref\">[35]</a></sup>任何极具破坏性的杂散电离，在有其他器官的紧密接近靶器官的情况下都十分危险（例如：头颈癌）。这种X射线照射对儿童尤其有害，因为他们的身体正在发育，并且在初次放疗后5年，将有30%的可能再次患恶性肿瘤。<sup><a href=\"#quote_36\" class=\"kx_ref\">[36]</a></sup> </p> \n<h3>剂量</h3> \n<p>光子放射治疗中使用的辐射量以戈瑞（Gy）计量，并且根据正在治疗的癌症的类型和阶段而变化。对于治疗性病例，实体上皮肿瘤的典型剂量范围为60-80 Gy，而淋巴瘤用20-40 Gy。 </p>\n<p>预防性（辅助）剂量通常在45-60 Gy左右（每次 1.8–2 Gy，乳腺癌、头颈癌。）当选择剂量时，放射肿瘤学家会考虑许多其他因素，包括患者是否正在接受化疗、伴随疾病、术前/术后是否进行放射治疗以及手术的成功程度。 </p>\n<p>处方剂量的输送参数将在治疗计划（剂量测定法的一部分）中确定。治疗计划通常使用专门的治疗计划软件在专用计算机上执行。根据辐射输送方法，可以使用多个角度或辐射源来合计所需的总剂量。治疗规划者将通过设计将均匀的处方剂量输送到肿瘤，并将对周围健康组织的剂量降至最低。 </p>\n<p>在放射治疗中，三维剂量分布可以使用称为凝胶剂量测定法的剂量测定法技术来评估。<sup><a href=\"#quote_37\" class=\"kx_ref\">[37]</a></sup> </p> \n<dl>\n <dt>\n  分次治疗\n </dt>\n</dl> \n<p>基于几个重要因素，放疗的总剂量是分次的（随时间分布）。分词治疗使得正常细胞有时间恢复，而肿瘤细胞在多次放疗之间的修复效率通常较低。分次治疗还允许在一次治疗期间处于细胞周期相对抗辐射阶段的肿瘤细胞在给予下一次放疗之前循环进入周期的敏感阶段。类似地，长期或急性低氧（因此更耐辐射）的肿瘤细胞可能在组分之间重新充氧，从而提高肿瘤细胞的杀伤能力。<sup><a href=\"#quote_38\" class=\"kx_ref\">[38]</a></sup> </p>\n<p>分次治疗方案在不同的放射治疗中心之间，甚至在个别医生之间均可能不同。在北美、澳大利亚和欧洲，成年人的典型分次计划是1.8-2 Gy一次，一周五天，每天1 Gy。对于某些类型的癌症，将分期计划延长太长时间会使肿瘤开始重新生长，对于这些肿瘤类型，包括头颈和宫颈鳞状细胞癌，放射治疗优选在一定时间内完成。对于儿童，典型的分数大小可以是1.5-1.8 Gy，因为较小的分次辐射剂量可以降低正常组织中迟发性副作用的发生率和严重性。 </p>\n<p>在某些情况下，在接近疗程结束时，每天进行两次分次治疗。这种方案被称为伴随强化疗法或超分割，用于肿瘤较小时，因为小型的肿瘤再生更快，特别是头颈部的肿瘤。 </p>\n<p>接受姑息性放疗治疗单纯疼痛性骨转移的患者不应接受超过一部分的放疗。<sup><a href=\"#quote_39\" class=\"kx_ref\">[39]</a></sup>单次治疗提供了与多次治疗相当的疼痛缓解和发病率结果，对于预期寿命有限的患者，单次治疗是改善患者舒适度的最佳方法。<sup><a href=\"#quote_39\" class=\"kx_ref\">[39]</a></sup> </p> \n<dl>\n <dt>\n  分次治疗计划\n </dt>\n</dl> \n<p>目前越来越多地使用，相关研究较多的分次计划是低分割。这是一种将总辐射剂量分成较大剂量的放射治疗。典型剂量因癌症类型而异，从2.2 Gy至20 Gy不等，后者的典型应用是颅内病变的立体定向治疗（立体定向消融体放疗，或SABR——也称为SBRT，或立体定向体放疗）或颅内病变的SRS（立体定向放射外科）。低分割的基本原理是利用一些肿瘤的放射敏感性，通过剥夺肿瘤原细胞繁殖所需的时间来降低局部复发的可能性。<sup><a href=\"#quote_40\" class=\"kx_ref\">[40]</a></sup>值得一提的是，立体定向治疗旨在通过消融过程破坏克隆原细胞，即放疗的目的是直接破坏肿瘤细胞，而不是像常规放射治疗那样反复中断肿瘤细胞分裂（凋亡）的过程。 </p> \n<p><strong>基于目标灵敏度的剂量估计</strong></p> \n<p>不同类型的癌症具有不同的辐射敏感性。然而，基于活检样本的基因组或蛋白质组分析预测灵敏度十分困难。<sup><a href=\"#quote_41\" class=\"kx_ref\">[41]</a></sup><sup><a href=\"#quote_42\" class=\"kx_ref\">[42]</a></sup>目前已发现微生物中的辐射保护由锰和小有机代谢物的非酶复合物提供，这为基因组学和蛋白质组学提供了另一种方法。<sup><a href=\"#quote_43\" class=\"kx_ref\">[43]</a></sup>科学家们发现锰的含量和变化（可通过电子顺磁共振测量）是辐射敏感性的良好预测因子，这一发现同样适用于人类细胞。<sup><a href=\"#quote_44\" class=\"kx_ref\">[44]</a></sup>经证实，总细胞锰含量及其变化可推断的不同肿瘤细胞的放射敏感性，这一发现可能有助于制定更精确的放射剂量，改善癌症患者的治疗。<sup><a href=\"#quote_45\" class=\"kx_ref\">[45]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14996359266435337","title":"类型","versionId":"14996359232880913","lemmaId":11137,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76052688,"name":"王一鑫","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576234526,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>迄今为止，放射治疗的三种主要类型是： </p> \n<ul>\n <li>外束放射疗法 （EBRT或XRT）或远程疗法；</li> \n <li>近距离放射疗法或密封源放射疗法；</li> \n <li>全身放射性同位素疗法或未密封源放射疗法。</li>\n</ul> \n<p>各种类型的差异与辐射源的位置有关；在体外，近距离治疗使用密封放射源精确放置在治疗区域，全身放射性同位素通过输注或口服给药。近距离治疗可以通过放射源的临时或永久放置实现。临时源的放置通常使用一种称为后装的技术。在后装过程中，通过外科手术将中空管或施放器放置在待治疗的器官中，并且在施放器植入后将放射源装入施放器中。这最大限度地减少了卫生保健人员的辐射暴露。 </p>\n<p>粒子疗法是一种特殊的外束放射疗法，其中粒子是质子或更重的离子。 </p> \n<h3>外束放射疗法</h3> \n<p>以下三节涉及X射线治疗。 </p> \n<p><strong>常规外束放射疗法</strong></p> \n<p></p><p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"258\" img_width=\"213\" titlename=\"一种远程治疗辐射胶囊，由以下物质组成： 一个 符合国际标准的放射源容器 （通常为铅制品）， 一个扣环 一个远程治疗 ”源“， 包括 焊接在一起的两个嵌套不锈钢罐， 上下各有一个不锈钢盖子，包裹 一个防护性屏障（通常由铀或钨合金制成）， 以及一个装有放射源的圆柱体，通常是 钴-60。“放射源”的直径通常为 30 mm.\" data-src=\"https://img02.sogoucdn.com/app/a/200698/sogou_science_16727\"> </p><p></p> \n<p>传统的外部束放射治疗（2DXRT）是通过使用产生高能X射线的千伏治疗X射线单元或医用直线加速器的二维束来进行的。<sup><a href=\"#quote_46\" class=\"kx_ref\">[46]</a></sup><sup><a href=\"#quote_47\" class=\"kx_ref\">[47]</a></sup>2DXRT主要由从多个方向导向患者的单束辐射组成：通常是正面或背面，以及两侧。 </p>\n<p>此处的“传统”指的是在一个被称为模拟器的经过特别校准的诊断X光机上计划或模拟治疗的方式，因为它再现了直线加速器的动作（或有时通过目测），并对建立的辐射束排列（通常较好）进行调整，以实现所需的<i>治疗计划</i>。模拟的目的是精确地瞄准或定位要治疗的区域。这种技术已经很成熟，并且通常快速可靠。但人担忧的是，一些高剂量治疗可能需要考虑靠近目标肿瘤的健康组织的辐射毒性能力。 </p>\n<p>类似问题的例子包括前列腺的化疗，考虑到相邻直肠的放射灵敏度，使用2DXRT计划，安全处方的剂量不容易实现肿瘤控制。在CT发明之前，医生和物理学家对传递给癌组织和健康组织的真实辐射剂量的了解有限。因此，三维适形放射治疗正在成为许多肿瘤部位的标准治疗方法。最近，还使用了其他形式的成像，包括磁共振成像、正电子发射断层扫描、SPECT和超声波。<sup><a href=\"#quote_48\" class=\"kx_ref\">[48]</a></sup> </p> \n<p><strong>立体定向辐射</strong></p> \n<p>立体定向放射是一种特殊类型的外束放射治疗。它使用聚焦辐射束，通过分辨率极高的成像扫描确定肿瘤范围。放射肿瘤学家通常在神经外科医生的帮助下对大脑或脊柱中的肿瘤进行立体定向治疗。 </p>\n<p>立体定向辐射有两种类型。一种是<b>立体定向放射外科手术，</b>即医生对大脑或脊柱使用单个或多个立体定向放射治疗。另一种是<b>立体定向身体放射疗法</b>（SBRT），是指对身体（如肺）进行一次或多次立体定向放射治疗。<sup><a href=\"#quote_49\" class=\"kx_ref\">[49]</a></sup> </p>\n<p>一些医生表示，立体定向治疗的一个优点是，与通常需要6-11周的传统治疗相比，立体定向治疗可以在更短的时间内向癌症输送适量的辐射。此外，治疗的准确性极高，降低辐射对健康组织的影响。立体定向治疗的一个问题是它们只适用于某些小肿瘤。 </p>\n<p>立体定向治疗的名称可能有些令人困惑，因为许多医院称这种治疗为制造商的名字，而不是称之为SRS或SBRT。这些治疗的品牌（技术）包括Axesse、赛博刀、伽玛刀、诺瓦利斯、Primatom、Synergy、 X-刀、断层扫描、Trilogy和 truebam 。<sup><a href=\"#quote_50\" class=\"kx_ref\">[50]</a></sup>随着设备制造商不断开发新的专门技术来治疗癌症，这个列表也随之改变。 </p> \n<p><strong>虚拟仿真和三维适形放射治疗</strong></p> \n<p>使用专门的CT和/或MRI扫描仪和规划软件在三维空间描绘肿瘤和相邻正常结构的能力彻底改变了放射治疗治疗的规划。<sup><a href=\"#quote_51\" class=\"kx_ref\">[51]</a></sup> </p>\n<p>虚拟仿真是放疗规划的最基本形式，相较传统X射线，它可以更精确地放置辐射束。传统X射线通常难以评估软组织结构，也难以保护正常组织。 </p>\n<p>虚拟仿真的一个显著提升是<b>三维适形放射治疗，</b>使用多叶准直器 （MLC）和可变数量的光束，将每个辐射光束在束流方向观（BEV）上与肿瘤靶区轮廓相符合。当治疗区域符合肿瘤的形状时，辐射对周围正常组织的相对毒性降低，从而可以将比传统技术更高剂量的辐射递送到肿瘤。<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup> </p> \n<p><strong>强度调制放射疗法（IMRT）</strong></p> \n<p></p><p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"225\" img_width=\"300\" titlename=\"瓦里安 TruBeam 直线加速器，用于输送IMRT\" data-src=\"https://img03.sogoucdn.com/app/a/200698/sogou_science_16729\"> </p><p></p> \n<p>强度调制放射疗法（IMRT）是一种先进的高精度辐射，是下一代三维阴极射线管。<sup><a href=\"#quote_52\" class=\"kx_ref\">[52]</a></sup>IMRT还提高了使治疗体积符合凹形肿瘤形状的能力，<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup>例如当肿瘤包裹在诸如脊髓或主要器官或血管的脆弱结构周围时。<sup><a href=\"#quote_53\" class=\"kx_ref\">[53]</a></sup>计算机控制的X射线加速器将精确的辐射剂量分配给恶性肿瘤或肿瘤内的特定区域。使用高度定制的计算应用程序来执行优化和治疗模拟（治疗计划）来确定辐射输送模式。通过控制或调节辐射束的强度，辐射剂量与肿瘤的三维形状一致。肿瘤靶区附近的辐射剂量强度增加，而相邻正常组织受到的辐射则可得到减少或完全避免。这样可以达到比3DCRT更好的肿瘤靶向性、更少的副作用和更好的治疗结果。 </p>\n<p>3DCRT仍然广泛用于许多身体部位，但IMRT也越来越多地应用于更复杂的身体部位，如中枢神经系统、头颈部、前列腺、乳房和肺。但IMRT所受的限制之一是，需要有经验的医务人员，且花费更多时间。这是因为医生每次均必须通过手动方式在整个疾病部位描绘一幅CT图像，这可能比3DCRT准备时间长得多。随后，医学物理学家和剂量学家必须参与制定一个可行的治疗计划。此外，自20世纪90年代末以来，IMRT技术仅在商业上使用，即使在最先进的癌症中心也是如此，因此在实施IMRT计划之前，没有在住院学习期间学习过该项技术的放射肿瘤医生必须接受额外的培训。 </p>\n<p>越来越多的证据表明，对于大多数肿瘤，上述两种技术中的任何一种都比传统放射治疗（2DXRT）更能提高存活率，并降低正常组织毒性。在皇家马斯登医院的克里斯托弗·纳特教授进行的一系列关键试验中，头颈癌尤其如此。这两种技术都能够增加剂量，并潜在地增加效用。但人们仍有顾虑，特别是对IMRT，<sup><a href=\"#quote_54\" class=\"kx_ref\">[54]</a></sup>正常组织辐射暴露量的增加以及随之而来的继发恶性肿瘤的可能性。对成像准确性的过度自信可能会增加病变遗漏的可能性，这些病变在计划扫描中是不可见的（因此不包括在治疗计划中），以及在治疗期间患者的移动（例如，由于呼吸或患者制动不充分）。目前正在开发新的技术来更好地控制这种不确定性——例如，实时成像与治疗光束的实时调整相结合。这项新技术被称为图像引导放射疗法 （IGRT）或四维放射疗法。 </p>\n<p>另一种技术是实时跟踪和定位植入肿瘤内部或附近的一个或多个小型可植入电子设备。有各种类型的医用可植入装置用于此目的。其可以是一个磁性应答器，检测由几个发射线圈产生的磁场，然后将测量结果传输回定位系统以确定位置。<sup><a href=\"#quote_55\" class=\"kx_ref\">[55]</a></sup>植入式设备也可以是发送射频信号的小型无线发射器，然后该射频信号将被传感器阵列接收并用于肿瘤位置的定位和实时跟踪。<sup><a href=\"#quote_56\" class=\"kx_ref\">[56]</a></sup><sup><a href=\"#quote_57\" class=\"kx_ref\">[57]</a></sup> </p> \n<p><strong>容积调制电弧疗法（VMAT）</strong></p> \n<p>容积调制电弧疗法（VMAT）是2007年引入的一种放射技术<sup><a href=\"#quote_58\" class=\"kx_ref\">[58]</a></sup>，其可以在目标肿瘤的覆盖和正常组织的分辨上实现高度适形的剂量分布。该技术的特异性来自治疗过程中对三个参数的修改。即通过旋转台架（通常是360个旋转场，带有一个或多个弧）、用多叶准直器（“滑动窗口”移动系统）改变光束的速度和形状以及医用直线加速器的通量输出率（剂量率）来传递辐射。与传统的静态场强调制放射疗法（IMRT）相比，VMAT在患者治疗方面具有减少放射输送时间的优势。<sup><a href=\"#quote_59\" class=\"kx_ref\">[59]</a></sup><sup><a href=\"#quote_60\" class=\"kx_ref\">[60]</a></sup>VMAT和传统IMRT在保存健康组织和高危器官方面的更多地取决于癌症类型。在治疗鼻咽癌、口咽癌和下咽癌时，VMAT可以提供与IMRT同等或更好的OAR保护。<sup><a href=\"#quote_58\" class=\"kx_ref\">[58]</a></sup><sup><a href=\"#quote_59\" class=\"kx_ref\">[59]</a></sup><sup><a href=\"#quote_60\" class=\"kx_ref\">[60]</a></sup>在前列腺癌的治疗中，OAR的保护效果则各有不同。<sup><a href=\"#quote_58\" class=\"kx_ref\">[58]</a></sup>一些研究显示VMAT更好，另一些研究则显示IMRT更好。<sup><a href=\"#quote_61\" class=\"kx_ref\">[61]</a></sup> </p> \n<p><strong>粒子疗法</strong></p> \n<p>在粒子治疗中（例如质子治疗），将高能电离粒子（质子或碳离子）导向目标肿瘤。<sup><a href=\"#quote_62\" class=\"kx_ref\">[62]</a></sup>当粒子穿透组织时，剂量增加，达到最大值（即布拉格尖峰）发生在粒子的末端附近范围，然后下降到（几乎）零。这种能量沉积分布的优点是仅有较少的能量沉积到目标组织周围的健康组织中。 </p> \n<p><strong>俄歇电子核素靶向疗法</strong></p> \n<p>俄歇疗法 （AT）使用非常高的剂量<sup><a href=\"#quote_63\" class=\"kx_ref\">[63]</a></sup>在原子尺度上提供分子修饰的电离辐射。AT在几个方面不同于传统的放射疗法；它既不依赖放射性核在细胞尺度上引起细胞辐射损伤，也不从多个方向通过多个外部辐射束向目标区域递送剂量，以减少目标组织/器官之外的辐射剂量。相反，使用AT在分子水平上原位递送非常高剂量的目的是作用于原位分子修饰，包括分子断裂和分子重排，例如堆叠结构的变化以及与所述分子结构相关的细胞代谢功能。 </p> \n<h3>接触式X射线近距离放射疗法</h3> \n<p>接触式X射线近距离放射疗法（也称为“CXB”、“电子近距离放射疗法”或“巴比隆技术”）是一种使用千伏电压的放射疗法X射线贴在肿瘤附近进行治疗直肠癌的方式。该过程包括将射线管插入肛门，然后以高剂量的X射线直接发射到直肠肿瘤，每两周一次。这项技术通常用于治疗可能不适合手术的患者的早期直肠癌。<sup><a href=\"#quote_64\" class=\"kx_ref\">[64]</a></sup><sup><a href=\"#quote_65\" class=\"kx_ref\">[65]</a></sup><sup><a href=\"#quote_66\" class=\"kx_ref\">[66]</a></sup>2015年NICE的一项审查发现，其主要副作用是约38%的病例发生出血，27%的病例发生辐射诱发的溃疡。<sup><a href=\"#quote_64\" class=\"kx_ref\">[64]</a></sup> </p> \n<h3>近距离放射疗法（密封源放射疗法）</h3> \n<p></p><p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"225\" img_width=\"300\" titlename=\"SAVI近距离放射治疗设备\" data-src=\"https://img04.sogoucdn.com/app/a/200698/sogou_science_16731\"> </p><p></p> \n<p>近距离治疗是通过将放射源放置在需要治疗的区域内或附近来实施的。近距离放射治疗作为一种有效的疗法，通常被用于宫颈，<sup><a href=\"#quote_67\" class=\"kx_ref\">[67]</a></sup>前列腺，<sup><a href=\"#quote_68\" class=\"kx_ref\">[68]</a></sup>乳房，<sup><a href=\"#quote_69\" class=\"kx_ref\">[69]</a></sup>和皮肤癌<sup><a href=\"#quote_70\" class=\"kx_ref\">[70]</a></sup>，也可用于治疗许多其他身体部位的肿瘤。<sup><a href=\"#quote_71\" class=\"kx_ref\">[71]</a></sup> </p>\n<p>在近距离放疗中，放射源被精确地直接放置在癌性肿瘤的位置。这意味着辐射只影响非常局部的区域，这减少了远离放射源的健康组织的辐射暴露。近距离放射治疗的这些特点提供了优于外部束放射治疗的优势——可以用非常高剂量的局部放射治疗肿瘤，同时降低对周围健康组织不必要的损伤。<sup><a href=\"#quote_71\" class=\"kx_ref\">[71]</a></sup><sup><a href=\"#quote_72\" class=\"kx_ref\">[72]</a></sup>近距离治疗的过程通常可以在比其他放射治疗技术更短的时间内完成。这有助于减少在每次放射治疗剂量间隔期间存活的癌细胞分裂和生长的机会。<sup><a href=\"#quote_72\" class=\"kx_ref\">[72]</a></sup> </p>\n<p>乳房近距离放射疗法就是一个很好的局限放射的例子，SAVI装置通过多个导管输送辐射剂量，每个导管都可以单独控制。与外束放射治疗和旧的乳房近距离放射治疗方法相比，这种方法减少了健康组织的暴露和由此产生的副作用。<sup><a href=\"#quote_73\" class=\"kx_ref\">[73]</a></sup> </p> \n<h3>非密封源放射疗法（全身放射性同位素疗法）</h3> \n<p>系统性放射性同位素治疗（RIT）是一种靶向治疗。靶向可能是由于同位素的化学性质，如放射性碘，它可以被甲状腺特异性吸收，相较其他身体器官要高一千倍。靶向也可以通过将放射性同位素附着到另一个分子或抗体上以将其引导到靶组织来实现。放射性同位素通过灌输（进入血流）或直接摄入体内。例如注入间碘苄基胍治疗成神经细胞瘤，口服碘-131治疗甲状腺癌或者甲状腺毒症、以及激素结合镥-177和钇-90治疗神经内分泌肿瘤（肽受体放射性核素疗法）。 </p>\n<p>另一个例子是将放射性钇-90或钬-166微球注入肝动脉，放射性栓塞肝肿瘤或肝转移。使用这些微球的治疗方法被称为“选择性内放射疗法”。微球直径约为30&nbsp;µm （人类头发直径的三分之一），并直接输送到向肿瘤供血的动脉中。这类治疗通过引导导管向上穿过腿部股动脉，再导航到所需的目标部位进行治疗。给肿瘤供血的血液会将微球直接运送到肿瘤，从而实现比传统全身化疗更具选择性的方法。目前有三种不同类型的微球： SIR-sphere ，TheraSphere 和QuiremSpheres。 </p>\n<p>全身放射性同位素疗法的主要用途是治疗癌症的骨转移。放射性同位素选择性地转移到受损骨骼区域，并保留正常未受累的骨骼。通常用于治疗骨转移的同位素是镭-223 ，<sup><a href=\"#quote_74\" class=\"kx_ref\">[74]</a></sup> 锶-89 和钐（<sup>153</sup>lexidronam。<sup><a href=\"#quote_75\" class=\"kx_ref\">[75]</a></sup> </p>\n<p>2002年，美国食品和药物管理局 （FDA）批准了抗CD20 的 ibritummab tiuxetan （泽缬氨酸） 与钇-90缀合的单克隆抗体。<sup><a href=\"#quote_76\" class=\"kx_ref\">[76]</a></sup>2003年，美国食品和药物管理局（FDA）批准了托西莫单抗/碘（<sup>131</sup>I） tositumomab方案（Bexxar），它是碘-131标记和未标记的抗CD20单克隆抗体的组合。<sup><a href=\"#quote_77\" class=\"kx_ref\">[77]</a></sup>这些药物是第一批被称为放射免疫疗法的药物，它们被批准用于治疗难治性非霍吉金斯淋巴瘤。 </p> \n<h3>术中放疗</h3> \n<p>术中放疗 （IORT）是将治疗水平的辐射施加到目标区域，例如癌症肿瘤，手术期间会将该区域直接暴露。<sup><a href=\"#quote_78\" class=\"kx_ref\">[78]</a></sup> </p> \n<p><strong>基本原理</strong></p> \n<p>IORT的基本原理是将高剂量辐射精确地输送到目标区域，同时尽量减少在IORT期间被转移或屏蔽的周围组织的暴露。传统的放射技术，例如手术切除肿瘤后的外照射（EBRT）有几个缺点：即便使用现代放射治疗计划，由于伤口腔的复杂定位，经常会错过应该施加最高剂量的肿瘤床。此外，手术切除肿瘤和EBRT之间的延迟可能会令肿瘤细胞有机会重新增殖。这些潜在的有害影响可以通过将辐射更精确地传递到目标组织来避免，从而导致剩余肿瘤细胞的立即被杀死。另一方面是伤口液体对肿瘤细胞有刺激作用。已有研究发现IORT可以抑制伤口液体的刺激作用。<sup><a href=\"#quote_79\" class=\"kx_ref\">[79]</a></sup> </p> \n<h3>深吸屏气</h3> \n<p>深吸屏气（DIBH）是一种在限制心脏和肺部辐射暴露的同时进行放射治疗的方法。<sup><a href=\"#quote_80\" class=\"kx_ref\">[80]</a></sup>它主要用于治疗左侧乳腺癌。这项技术包括患者在治疗期间屏住呼吸。包括两种基本方法：自由呼吸屏气和肺活量测量监测的深吸气屏气。<sup><a href=\"#quote_81\" class=\"kx_ref\">[81]</a></sup> </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16727?w=213&h=258&titlename=%E4%B8%80%E7%A7%8D%E8%BF%9C%E7%A8%8B%E6%B2%BB%E7%96%97%E8%BE%90%E5%B0%84%E8%83%B6%E5%9B%8A%EF%BC%8C%E7%94%B1%E4%BB%A5%E4%B8%8B%E7%89%A9%E8%B4%A8%E7%BB%84%E6%88%90%EF%BC%9A%20%E4%B8%80%E4%B8%AA%20%E7%AC%A6%E5%90%88%E5%9B%BD%E9%99%85%E6%A0%87%E5%87%86%E7%9A%84%E6%94%BE%E5%B0%84%E6%BA%90%E5%AE%B9%E5%99%A8%20%EF%BC%88%E9%80%9A%E5%B8%B8%E4%B8%BA%E9%93%85%E5%88%B6%E5%93%81%EF%BC%89%EF%BC%8C%20%E4%B8%80%E4%B8%AA%E6%89%A3%E7%8E%AF%20%E4%B8%80%E4%B8%AA%E8%BF%9C%E7%A8%8B%E6%B2%BB%E7%96%97%20%E2%80%9D%E6%BA%90%E2%80%9C%EF%BC%8C%20%E5%8C%85%E6%8B%AC%20%E7%84%8A%E6%8E%A5%E5%9C%A8%E4%B8%80%E8%B5%B7%E7%9A%84%E4%B8%A4%E4%B8%AA%E5%B5%8C%E5%A5%97%E4%B8%8D%E9%94%88%E9%92%A2%E7%BD%90%EF%BC%8C%20%E4%B8%8A%E4%B8%8B%E5%90%84%E6%9C%89%E4%B8%80%E4%B8%AA%E4%B8%8D%E9%94%88%E9%92%A2%E7%9B%96%E5%AD%90%EF%BC%8C%E5%8C%85%E8%A3%B9%20%E4%B8%80%E4%B8%AA%E9%98%B2%E6%8A%A4%E6%80%A7%E5%B1%8F%E9%9A%9C%EF%BC%88%E9%80%9A%E5%B8%B8%E7%94%B1%E9%93%80%E6%88%96%E9%92%A8%E5%90%88%E9%87%91%E5%88%B6%E6%88%90%EF%BC%89%EF%BC%8C%20%E4%BB%A5%E5%8F%8A%E4%B8%80%E4%B8%AA%E8%A3%85%E6%9C%89%E6%94%BE%E5%B0%84%E6%BA%90%E7%9A%84%E5%9C%86%E6%9F%B1%E4%BD%93%EF%BC%8C%E9%80%9A%E5%B8%B8%E6%98%AF%20%E9%92%B4-60%E3%80%82%E2%80%9C%E6%94%BE%E5%B0%84%E6%BA%90%E2%80%9D%E7%9A%84%E7%9B%B4%E5%BE%84%E9%80%9A%E5%B8%B8%E4%B8%BA%2030%20mm.","url":"https://web.archive.org/web/20221028212143/https://img02.sogoucdn.com/app/a/200698/sogou_science_16727","rw":213,"rh":258,"title":"一种远程治疗辐射胶囊，由以下物质组成： 一个 符合国际标准的放射源容器 （通常为铅制品）， 一个扣环 一个远程治疗 ”源“， 包括 焊接在一起的两个嵌套不锈钢罐， 上下各有一个不锈钢盖子，包裹 一个防护性屏障（通常由铀或钨合金制成）， 以及一个装有放射源的圆柱体，通常是 钴-60。“放射源”的直径通常为 30 mm.","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028212143/https://img03.sogoucdn.com/app/a/200698/sogou_science_16729?w=300&h=225&titlename=%E7%93%A6%E9%87%8C%E5%AE%89%20TruBeam%20%E7%9B%B4%E7%BA%BF%E5%8A%A0%E9%80%9F%E5%99%A8%EF%BC%8C%E7%94%A8%E4%BA%8E%E8%BE%93%E9%80%81IMRT","url":"https://web.archive.org/web/20221028212143/https://img03.sogoucdn.com/app/a/200698/sogou_science_16729","rw":300,"rh":225,"title":"瓦里安 TruBeam 直线加速器，用于输送IMRT","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028212143/https://img04.sogoucdn.com/app/a/200698/sogou_science_16731?w=300&h=225&titlename=SAVI%E8%BF%91%E8%B7%9D%E7%A6%BB%E6%94%BE%E5%B0%84%E6%B2%BB%E7%96%97%E8%AE%BE%E5%A4%87","url":"https://web.archive.org/web/20221028212143/https://img04.sogoucdn.com/app/a/200698/sogou_science_16731","rw":300,"rh":225,"title":"SAVI近距离放射治疗设备","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"14996359266435338","title":"历史","versionId":"14996359232880914","lemmaId":11137,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76052688,"name":"王一鑫","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576234526,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p></p><p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"343\" img_width=\"420\" titlename=\"1910年肺结核的x线治疗。在20世纪20年代之前，人们还不了解辐射的危害，它被用来治疗各种疾病。\" data-src=\"https://img03.sogoucdn.com/app/a/200698/sogou_science_16732\"> </p><p></p> \n<p>医学上使用放射疗法治疗癌症已经有100多年的历史，其最早可追溯到1895年威廉·伦琴发现X射线。<sup><a href=\"#quote_82\" class=\"kx_ref\">[82]</a></sup> 埃米尔·格拉布（芝加哥）于1896年成为第一个使用X射线治疗癌症的美国医生。<sup><a href=\"#quote_83\" class=\"kx_ref\">[83]</a></sup> </p>\n<p>放射治疗这一领域在20世纪初开始发展，主要是由于诺贝尔奖获奖科学家玛丽·居里（1867-1934）在1898年发现了放射性元素钋和镭。这开启了医学治疗和研究的新时代。<sup><a href=\"#quote_82\" class=\"kx_ref\">[82]</a></sup>在20世纪20年代，人们还不了解辐射暴露的危害，也很少使用防护措施。镭被认为具有广泛的治疗能力，放射疗法被应用于许多疾病。 </p>\n<p>在第二次世界大战之前，放射治疗的唯一实际辐射源是镭的“放射物”，即氡气体和射线管。体外放射治疗（远程治疗）开始于世纪之交，电压相对较低（&lt; 150&nbsp;kV） X射线机。人们发现，虽然浅表肿瘤可以用低电压X射线治疗，但更具穿透性、更高能量的射线需要到达体内的肿瘤，需要更高的电压。于是在20世纪20年代，使用200-500万伏管电压的正交电压X射线应运而生。要到达埋藏最深的肿瘤而不将介入的皮肤和组织暴露在危险的辐射剂量下，需要能量为1兆伏或以上，称为“兆伏”辐射。要产生所需的兆伏X射线，就要用到电压在300-500万伏特的X射线管，这需要大量昂贵的设备。兆伏X射线设备最早建于20世纪30年代末，但由于成本有限，仅限于几家机构。第一个安装在圣巴塞洛缪医院，伦敦在1937年使用，直到1960年，使用了一个30英尺长的X射线管，重10吨。镭可以产生兆伏γ射线，但是由于其在矿石中的含量低，所以极其罕见和昂贵。1937年，全世界放射治疗用镭的供应量为50克，价值80万美元，按2005年美元的价值计算则为5000万美元。 </p>\n<p>第二次世界大战期间曼哈顿计划促使了核反应堆的发明，这使得人造放射性同位素用于放射治疗成为可能。钴疗法，利用钴60（一种由反应堆中的普通钴金属辐照产生的放射性同位素）释放出的兆伏伽马射线进行的远距放射疗法，在20世纪50年代至80年代初彻底改变了这一领域。钴机器相对便宜、坚固且使用简单，但由于其5.27年的半衰期，机器中的钴大约每5年就要更换一次。 </p>\n<p>自20世纪40年代开发的医用线性粒子加速器在20世纪80年代开始取代X射线和钴元素，旧的疗法日渐衰落。第一台医用直线加速器于1953年在伦敦的汉默史密斯医院使用。<sup><a href=\"#quote_47\" class=\"kx_ref\">[47]</a></sup>直线加速器可以产生更高的能量，具有更多的准直光束，并且不会产生放射性废物以及随之而来的放射性同位素的处置问题。 </p>\n<p>随着高弗雷·豪斯费尔德发明计算机断层扫描，1971年，三维规划成为可能，并创造了从二维到三维辐射传输的转变。基于CT的规划让医生可以使用患者解剖结构的轴向断层图像更精确地确定剂量分布。随着新成像技术的出现，包括磁共振成像（20世纪70年代）和正电子发射断层摄影术（PET，20世纪80年代），放射治疗已经从三维适形转移到IMRT高精度放射线疗法（IMRT）和图像引导放射疗法（IGRT）断层疗法。这些进展使放射肿瘤学家能够更好地观察和定位肿瘤，从而获得更好的治疗效果、更多地保存患者器官保存以及更少的副作用。<sup><a href=\"#quote_84\" class=\"kx_ref\">[84]</a></sup> </p>\n<p>虽然在全球范围内放射治疗的普及率正在增加，但截至2017年，低收入和中等收入国家仍有一半以上的患者无法获得治疗。<sup><a href=\"#quote_85\" class=\"kx_ref\">[85]</a></sup> </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028212143/https://img03.sogoucdn.com/app/a/200698/sogou_science_16732?w=420&h=343&titlename=1910%E5%B9%B4%E8%82%BA%E7%BB%93%E6%A0%B8%E7%9A%84x%E7%BA%BF%E6%B2%BB%E7%96%97%E3%80%82%E5%9C%A820%E4%B8%96%E7%BA%AA20%E5%B9%B4%E4%BB%A3%E4%B9%8B%E5%89%8D%EF%BC%8C%E4%BA%BA%E4%BB%AC%E8%BF%98%E4%B8%8D%E4%BA%86%E8%A7%A3%E8%BE%90%E5%B0%84%E7%9A%84%E5%8D%B1%E5%AE%B3%EF%BC%8C%E5%AE%83%E8%A2%AB%E7%94%A8%E6%9D%A5%E6%B2%BB%E7%96%97%E5%90%84%E7%A7%8D%E7%96%BE%E7%97%85%E3%80%82","url":"https://web.archive.org/web/20221028212143/https://img03.sogoucdn.com/app/a/200698/sogou_science_16732","rw":420,"rh":343,"title":"1910年肺结核的x线治疗。在20世纪20年代之前，人们还不了解辐射的危害，它被用来治疗各种疾病。","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0}],"references":[{"id":1,"type":"book","title":"CK·博姆福德，IH·昆克尔，J·沃尔特。沃尔特和米勒的放射疗法教科书(第6版)，p311","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":2,"type":"book","title":"GP笔记本上的“辐射敏感性”http://www.gpnotebook.co.uk/simplepage.cfm?ID=2060451853","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":3,"type":"book","title":"patient.co.uk http://patient.info/doctor/radiotherapy 的“放射疗法——全球定位系统需要知道什么”","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":4,"type":"book","title":"Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F (2015). \"Metastatic melanoma - a review of current and future treatment options\". Acta Derm Venereol. 95 (5): 516–524. doi:10.2340/00015555-2035. PMID 25520039.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":5,"type":"book","title":"坎普豪森·卡，劳伦斯研究中心。《放射治疗原理》，帕兹杜尔R，瓦格纳LD，坎普豪森KA，霍斯金斯WJ(编辑)《癌症管理:多学科方法》。11版。2008.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":6,"type":"book","title":"Seidlitz, Annekatrin; Combs, Stephanie E.; Debus, Jürgen; Baumann, Michael (2016). \"Practice points for radiation oncology\". In Kerr, David J.; Haller, Daniel G.; van de Velde, Cornelis J. H.; Baumann, Michael. Oxford Textbook of Oncology (in 英语). Oxford University Press. p. 173. ISBN 9780191065101.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":7,"type":"book","title":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Darby, S.; McGale, P.; Correa, C.; Taylor, C.; Arriagada, R.; Clarke, M.; Cutter, D.; Davies, C.; Ewertz, M.; Godwin, J.; Gray, R.; Pierce, L.; Whelan, T.; Wang, Y.; Peto, R. (November 2011). \"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials\". The Lancet. 378 (9804): 1707–1716. doi:10.1016/S0140-6736(11)61629-2. PMC 3254252. PMID 22019144.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":8,"type":"book","title":"Mahmood SS (2016). \"Cardiovascular Complications of Cranial and Neck Radiation\". Current Treatment Options in Cardiovascular Medicine. 18 (45): 45. doi:10.1007/s11936-016-0468-4. PMID 27181400.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":9,"type":"book","title":"\"Radiation Therapy for Breast Cancer: Possible Side Effects\". Rtanswers.com. 2012-03-15. Archived from the original on 2012-03-01. Retrieved 2012-04-20.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":10,"type":"book","title":"Lee VH, Ng SC, Leung TW, Au GK, Kwong DL (2012). \"Dosimetric predictors of radiation-induced acute nausea and vomiting in IMRT for nasopharyngeal cancer\". International Journal of Radiation Oncology, Biology, Physics. 84 (1): 176–82. doi:10.1016/j.ijrobp.2011.10.010. PMID 22245210.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":11,"type":"book","title":"\"Archived copy\". Archived from the original on 2012-03-30. Retrieved 2012-05-02.CS1 maint: Archived copy as title (link)常见辐射副作用","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":12,"type":"book","title":"\"Radiation Therapy Side Effects and Ways to Manage them\". National Cancer Institute. 2007-04-20. Retrieved 2012-05-02.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":13,"type":"book","title":"Hall, Eric J. (2000). Radiobiology for the radiologist. Philadelphia: Lippincott Williams Wilkins. p. 351. ISBN 9780781726498.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":14,"type":"book","title":"Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I, De la Riva S, Sola J, Bilbao JI, de Luis E, Sangro B (2007). \"Gastroduodenal injury after radioembolization of hepatic tumors\". The American Journal of Gastroenterology. 102 (6): 1216–20. doi:10.1111/j.1572-0241.2007.01172.x. PMID 17355414.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":15,"type":"book","title":"Yip D, Allen R, Ashton C, Jain S (2004). \"Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer\". Journal of Gastroenterology and Hepatology. 19 (3): 347–9. doi:10.1111/j.1440-1746.2003.03322.x. PMID 14748889.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":16,"type":"book","title":"Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, Nunez R, Habbu A, Liu D, Ross W, Cohen AM, Censullo M (2007). \"Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy\". Journal of Vascular and Interventional Radiology : JVIR. 18 (4): 553–61, quiz 562. doi:10.1016/j.jvir.2007.02.002. PMID 17446547.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":17,"type":"book","title":"Arepally A, Chomas J, Kraitchman D, Hong K (2013). \"Quantification and reduction of reflux during embolotherapy using an antireflux catheter and tantalum microspheres: Ex vivo analysis\". Journal of Vascular and Interventional Radiology : JVIR. 24 (4): 575–80. doi:10.1016/j.jvir.2012.12.018. PMID 23462064.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":18,"type":"book","title":"Meek AG (1998). \"Breast radiation therapy and lymphedema\". Cancer. 83 (12 Suppl American): 2788–97. doi:10.1002/(SICI)1097-0142(19981215)83:12B+<2788::AID-CNCR27>3.0.CO;2-I. PMID 9874399.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":19,"type":"book","title":"Taylor CW, Nisbet A, McGale P, Darby SC (December 2007). \"Cardiac exposures in breast cancer radiotherapy: 1950s-1990s\". International Journal of Radiation Oncology, Biology, Physics. 69 (5): 1484–95. doi:10.1016/j.ijrobp.2007.05.034. PMID 18035211.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":20,"type":"book","title":"Weintraub NL, Jones WK, Manka D (March 2010). \"Understanding radiation-induced vascular disease\". Journal of the American College of Cardiology. 55 (12): 1237–9. doi:10.1016/j.jacc.2009.11.053. PMC 3807611. PMID 20298931.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":21,"type":"book","title":"Klee NS, McCarthy CG, Martinez-Quinones P, Webb RC (November 2017). \"Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy\". Therapeutic Advances in Cardiovascular Disease. 11 (11): 297–317. doi:10.1177/1753944717729141. PMC 5933669. PMID 28911261.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":22,"type":"book","title":"\"Late Effects of Treatment for Childhood Cancer\". National Cancer Institute. 12 April 2012. Retrieved 7 June 2012.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":23,"type":"book","title":"Hauer-Jensen M, Denham JW, Andreyev HJ (2014). \"Radiation enteropathy--pathogenesis, treatment and prevention\". Nat Rev Gastroenterol Hepatol. 11 (8): 470–9. doi:10.1038/nrgastro.2014.46. PMC 4346191. PMID 24686268.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":24,"type":"book","title":"Fuccio L, Guido A, Andreyev HJ (2012). \"Management of intestinal complications in patients with pelvic radiation disease\". Clin. Gastroenterol. Hepatol. 10 (12): 1326–1334.e4. doi:10.1016/j.cgh.2012.07.017. PMID 22858731.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":25,"type":"book","title":"Christian Custodio; Cody Christian Andrews (August 1, 2017). \"Radiation Plexopathy\". American Academy of Physical Medicine and Rehabilitation.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":26,"type":"book","title":"Delanian S, Lefaix JL, Pradat PF (December 2012). \"Radiation-induced neuropathy in cancer survivors\". Radiotherapy and Oncology. 105 (3): 273–82. doi:10.1016/j.radonc.2012.10.012. PMID 23245644.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":27,"type":"book","title":"Nieder C, Milas L, Ang KK (2000). \"Tissue tolerance to reirradiation\". Semin Radiat Oncol. 10 (3): 200–9. doi:10.1053/srao.2000.6593. PMID 11034631.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":28,"type":"book","title":"Arnon J, Meirow D, Lewis-Roness H, Ornoy A (2001). \"Genetic and teratogenic effects of cancer treatments on gametes and embryos\". Human Reproduction Update. 7 (4): 394–403. doi:10.1093/humupd/7.4.394. PMID 11476352. [1]","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":29,"type":"book","title":"Fernandez A, Brada M, Zabuliene L, Karavitaki N, Wass JA (September 2009). \"Radiation-induced hypopituitarism\" (PDF). Endocr. Relat. Cancer. 16 (3): 733–72. doi:10.1677/ERC-08-0231. PMID 19498038.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":30,"type":"book","title":"Bogdanich W, Ruiz RR (25 February 2010). \"Missouri Hospital Reports Errors in Radiation Doses\". The New York Times. Retrieved 26 February 2010.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":31,"type":"book","title":"\"What Questions Should I Ask My Doctor?: Questions to ask after treatment ends\". Rtanswers.com. 2010-09-22. Archived from the original on 2012-04-12. Retrieved 2012-04-20.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":32,"type":"book","title":"Eaton C, Seegenschmiedt MH, Bayat A, Gabbiani G, Werker P, Wach W (2012). Dupuytren's Disease and Related Hyperproliferative Disorders: Principles, Research, and Clinical Perspectives. Springer. pp. 355–364. ISBN 978-3-642-22696-0.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":33,"type":"book","title":"Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D (2002). \"Impact of tumor hypoxia and anemia on radiation therapy outcomes\". Oncologist. 7 (6): 492–508. doi:10.1634/theoncologist.7-6-492. PMID 12490737.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":34,"type":"book","title":"Sheehan JP, Shaffrey ME, Gupta B, Larner J, Rich JN, Park DM (2010). \"Improving the radiosensitivity of radioresistant and hypoxic glioblastoma\". Future Oncology. 6 (10): 1591–1601. doi:10.2217/fon.10.123. PMID 21062158.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":35,"type":"book","title":"柯蒂斯·雷、弗里德曼·DM、罗恩·E、里斯·拉格、哈克·DG、爱德华兹·BK、塔克·马、小弗劳米尼·JF(编辑)。癌症幸存者中的新恶性肿瘤:SEER癌症登记处，1973-2000。国家癌症研究所。NIH Publ。号码05-5302。马里兰州贝塞斯达，2006年。","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":36,"type":"book","title":"https://web.archive.org/web/20221028212143/http://www . Helmholtz-muen Chen . de/file admin/ISS/PDF/Riiskoanalyse/乔治敦/Robison.pdf","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":37,"type":"book","title":"Baldock C, De Deene Y, Doran S, Ibbott G, Jirasek A, Lepage M, McAuley KB, Oldham M, Schreiner LJ (2010). \"Polymer gel dosimetry\". Physics in Medicine and Biology. 55 (5): R1–63. Bibcode:2010PMB....55R...1B. doi:10.1088/0031-9155/55/5/r01. PMC 3031873. PMID 20150687.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":38,"type":"book","title":"Ang, K. Kian (October 1998). \"Altered fractionation trials in head and neck cancer\". Seminars in Radiation Oncology. 8 (4): 230–236. doi:10.1016/S1053-4296(98)80020-9.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":39,"type":"book","title":"American Academy of Hospice and Palliative Medicine, \"Five Things Physicians and Patients Should Question\", Choosing Wisely: an initiative of the ABIM Foundation, American Academy of Hospice and Palliative Medicine, retrieved August 1, 2013，引用了 Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, Howell D, Konski A, Kachnic L, Lo S, Sahgal A, Silverman L, von Gunten C, Mendel E, Vassil A, Bruner DW, Hartsell W, American Society for Radiation Oncology (ASTRO) (2011). \"Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline\". International Journal of Radiation Oncology*Biology*Physics. 79 (4): 965–976. doi:10.1016/j.ijrobp.2010.11.026. PMID 21277118.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":40,"type":"book","title":"[·波拉克、艾伦和曼苏尔·艾哈迈德。低分馏:科学概念和临床经验。1号。埃利科特城:极限出版社，2011年]","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":41,"type":"book","title":"Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF (February 2017). \"A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study\". The Lancet. Oncology. 18 (2): 202–211. doi:10.1016/S1470-2045(16)30648-9. PMID 27993569.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":42,"type":"book","title":"Lacombe J, Azria D, Mange A, Solassol J (February 2013). \"Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes\". Expert Review of Proteomics. 10 (1): 33–42. doi:10.1586/epr.12.68. PMID 23414358.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":43,"type":"book","title":"Daly MJ (March 2009). \"A new perspective on radiation resistance based on Deinococcus radiodurans\". Nature Reviews. Microbiology. 7 (3): 237–45. doi:10.1038/nrmicro2073. PMID 19172147.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":44,"type":"book","title":"Sharma A, Gaidamakova EK, Grichenko O, Matrosova VY, Hoeke V, Klimenkova P, Conze IH, Volpe RP, Tkavc R, Gostinčar C, Gunde-Cimerman N, DiRuggiero J, Shuryak I, Ozarowski A, Hoffman BM, Daly MJ (October 2017). \"2+, gauged by paramagnetic resonance\". Proceedings of the National Academy of Sciences of the United States of America. 114 (44): E9253–E9260. doi:10.1073/pnas.1713608114. PMC 5676931. PMID 29042516.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":45,"type":"book","title":"Doble PA, Miklos GL (July 2018). \"Distributions of manganese in diverse human cancers provide insights into tumour radioresistance\". Metallomics. 10 (9): 1191–1210. doi:10.1039/c8mt00110c. PMID 30027971.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":46,"type":"book","title":"Hill R, Healy B, Holloway L, Kuncic Z, Thwaites D, Baldock C (March 2014). \"Advances in kilovoltage x-ray beam dosimetry\". Physics in Medicine and Biology. 59 (6): R183–231. Bibcode:2014PMB....59R.183H. doi:10.1088/0031-9155/59/6/R183. PMID 24584183.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":47,"type":"book","title":"Thwaites DI, Tuohy JB (July 2006). \"Back to the future: the history and development of the clinical linear accelerator\". Physics in Medicine and Biology. 51 (13): R343–62. Bibcode:2006PMB....51R.343T. doi:10.1088/0031-9155/51/13/R20. PMID 16790912.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":48,"type":"book","title":"Lagendijk JJ, Raaymakers BW, Van den Berg CA, Moerland MA, Philippens ME, van Vulpen M (November 2014). \"MR guidance in radiotherapy\". Physics in Medicine and Biology. 59 (21): R349–69. Bibcode:2014PMB....59R.349L. doi:10.1088/0031-9155/59/21/R349. PMID 25322150.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":49,"type":"book","title":"\"American Society for Radiation Oncology\" (PDF). Astro.org. Archived from the original (PDF) on 2010-06-13. Retrieved 2012-04-20.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":50,"type":"book","title":"\"Treatment Types: Stereotactic Radiation Therapy\". Rtanswers.com. 2010-01-04. Archived from the original on 2012-05-09. Retrieved 2012-04-20.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":51,"type":"book","title":"Bucci MK, Bevan A, Roach M (2005). \"Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond\". CA Cancer J Clin. 55 (2): 117–34. doi:10.3322/canjclin.55.2.117. PMID 15761080.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":52,"type":"book","title":"Galvin JM, Ezzell G, Eisbrauch A, Yu C, Butler B, Xiao Y, Rosen I, Rosenman J, Sharpe M, Xing L, Xia P, Lomax T, Low DA, Palta J (Apr 2004). \"Implementing IMRT in clinical practice: a joint document of the American Society for Therapeutic Radiology and Oncology and the American Association of Physicists in Medicine\". Int J Radiat Oncol Biol Phys. 58 (5): 1616–34. doi:10.1016/j.ijrobp.2003.12.008. PMID 15050343.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":53,"type":"book","title":"\"Intensity Modulated Radiation Therapy\". Irsa.org. Retrieved 2012-04-20.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":54,"type":"book","title":"Hall EJ, Wuu CS (2003). \"Radiation-induced second cancers: the impact of 3D-CRT and IMRT\". Int. J. Radiat. Oncol. Biol. Phys. 56 (1): 83–8. doi:10.1016/S0360-3016(03)00073-7. PMID 12694826.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":55,"type":"book","title":"Wing-Fai Loke; Tae-Young Choi; Teimour Maleki; Lech Papiez; Babak Ziaie; Byunghoo Jung (2010). \"Magnetic Tracking System for Radiation Therapy\". IEEE Transactions on Biomedical Circuits and Systems. 4 (4): 223–231. doi:10.1109/TBCAS.2010.2046737. PMID 23853368.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":56,"type":"book","title":"M. Pourhomayoun; M. L. Fowler; Z. Jin. \"A Novel Method for Tumor Localization and Tracking in Radiation Therapy\". IEEE Asilomar Conference on Signals, Systems and Computers, 2012","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":57,"type":"book","title":"M. Pourhomayoun; M. L. Fowler; Z. Jin. \"Robustness Analysis of Sparsity Based Tumor Localization under Tissue Configuration Uncertainty\". IEEE Signal Processing in Medicine and Biology Symposium (SPMB12), 2012","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":58,"type":"book","title":"Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A (Nov 2011). \"Volumetric modulated arc therapy: a review of current literature and clinical use in practice\". The British Journal of Radiology. 84 (1007): 967–96. doi:10.1259/bjr/22373346. PMC 3473700. PMID 22011829.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":59,"type":"book","title":"Bertelsen A, Hansen CR, Johansen J, Brink C (May 2010). \"Single Arc Volumetric modulated Arc therapy of head and neck cancer\". Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology. 95 (2): 142–8. doi:10.1016/j.radonc.2010.01.011. PMID 20188427.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":60,"type":"book","title":"VanGestel D, VanVliet-Vroegindeweij C, VanDenHeuvel F, Crijns W, Coelmont A, DeOst B, Holt A, Lamers E, Geussens Y, Nuyts S, VanDenWeyngaert D, VanDenWyngaert T, Vermorken JB, Gregoire V (Feb 2013). \"RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison\". Radiation Oncology. 8 (37). doi:10.1186/1748-717X-8-37.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":61,"type":"book","title":"Biegala M, Hydzik A (2016). \"Analysis of dose distribution in organs at risk in patients with prostate cancer treated with the intensity-modulated radiation therapy and arc technique\". Journal of Medical Physics. 41 (3): 198–204. doi:10.4103/0971-6203.189490. PMC 5019039.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":62,"type":"book","title":"Laurance, Jeremy (12 January 2009). \"Brain tumor patient 'unaware' treatment was available on NHS\". The Independent. Archived from the original on 22 June 2009. Retrieved 10 April 2009.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":63,"type":"book","title":"Kereiakes JG, Rao DV; Rao (1992). \"Auger electron dosimetry: report of AAPM Nuclear Medicine Committee Task Group No. 6\". Med Phys. 19 (6): 1359. Bibcode:1992MedPh..19.1359K. doi:10.1118/1.596925. PMID 1461197.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":64,"type":"book","title":"\"Contact X-ray Brachytherapy for early rectal cancer\". National Institute for Health and Care Excellence. September 2015.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":65,"type":"book","title":"Sun Myint A, Gerard J, Myerson RJ (2014). \"Contact X-Ray Brachytherapy for Rectal Cancer\". In Longo WE, Reddy V, Audisio RA. Modern Management of Cancer of the Rectum (in 英语). Springer. pp. 109ff. ISBN 9781447166092.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":66,"type":"book","title":"American Association of Physicists in Medicine (February 2009). \"The 2007 AAPM response to the CRCPD request for recommendations for the CRCPD's model regulations for electronic brachytherapy\" (PDF). American Association of Physicists in Medicine. Retrieved 17 April 2010.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":67,"type":"book","title":"Gerbaulet A, et al. (2005). \"Cervix carcinoma\". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium: ACCO.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":68,"type":"book","title":"Ash D, et al. (2005). \"Prostate cancer\". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium: ACCO.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":69,"type":"book","title":"Van Limbergen E, et al. (2005). \"Breast cancer\". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium: ACCO.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":70,"type":"book","title":"Van Limbergen E, et al. (2005). \"Skin cancer\". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium: ACCO.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":71,"type":"book","title":"Gerbaulet A, et al. (2005). \"General aspects\". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium: ACCO.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":72,"type":"book","title":"Stewart AJ; et al. (2007). \"Radiobiological concepts for brachytherapy\". In Devlin P. Brachytherapy. Applications and Techniques. Philadelphia: LWW.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":73,"type":"book","title":"Yashar CM, Blair S, Wallace A, Scanderbeg D (2009). \"Initial clinical experience with the Strut-Adjusted Volume Implant brachytherapy applicator for accelerated partial breast irradiation\". Brachytherapy. 8 (4): 367–72. doi:10.1016/j.brachy.2009.03.190. PMID 19744892.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":74,"type":"book","title":"Parker, Christopher (July 18, 2013). \"Alpha Emiiter Radium-223 and Survival in Metastatic Prostate Cancer\". New England Journal of Medicine. 369 (3): 213–23. doi:10.1056/NEJMoa1213755.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":75,"type":"book","title":"Sartor O (2004). \"Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease\". Rev Urol. 6 Suppl 10 (Suppl 10): S3–S12. PMC 1472939. PMID 16985930.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":76,"type":"book","title":"Fda批准首个治疗非霍奇金淋巴瘤的放射性药物产品 Archived 1月 19, 2009 at the Wayback Machine","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":77,"type":"book","title":"托西托姆巴和碘I 131托西托姆巴-产品批准信息-许可行动 Archived 5月 13, 2009 at the Wayback Machine","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":78,"type":"book","title":"Dutta SW, Showalter SL, Showalter TN, Libby B, Trifiletti DM (April 2017). \"Intraoperative radiation therapy for breast cancer patients: current perspectives\". Breast Cancer. 9: 257–263. doi:10.2147/BCTT.S112516. PMC 5402914. PMID 28458578.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":79,"type":"book","title":"Belletti B, Vaidya JS, D'Andrea S, Entschladen F, Roncadin M, Lovat F, Berton S, Perin T, Candiani E, Reccanello S, Veronesi A, Canzonieri V, Trovò MG, Zaenker KS, Colombatti A, Baldassarre G, Massarut S (March 2008). \"Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding\". Clinical Cancer Research. 14 (5): 1325–32. doi:10.1158/1078-0432.CCR-07-4453. PMID 18316551.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":80,"type":"book","title":"Hanley J, Debois MM, Mah D, Mageras GS, Raben A, Rosenzweig K, Mychalczak B, Schwartz LH, Gloeggler PJ, Lutz W, Ling CC, Leibel SA, Fuks Z, Kutcher GJ (October 1999). \"Deep inspiration breath-hold technique for lung tumors: the potential value of target immobilization and reduced lung density in dose escalation\". International Journal of Radiation Oncology, Biology, Physics. 45 (3): 603–11. doi:10.1016/S0360-3016(99)00154-6. PMID 10524412.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":81,"type":"book","title":"\"Deep Inspiration Breath-hold\". Genesis Care. Retrieved 14 January 2016.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":82,"type":"book","title":"\"University of Alabama at Birmingham Comprehensive Cancer Center, History of Radiation Oncology\". Archived from the original (from the Wayback Machine) on 2008-01-05.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":83,"type":"book","title":"\"Pioneer in X-Ray Therapy\". Science. New Series. 125 (3236): 18–19. 4 January 1957. Bibcode:1957Sci...125T..18.. doi:10.1126/science.125.3236.18. JSTOR 1752791.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":84,"type":"book","title":"\"History of Radiation Therapy: The Evolution of Therapeutic Radiology\". Rtanswers.com. 2010-03-31. Archived from the original on 2012-03-01. Retrieved 2012-04-20.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":85,"type":"book","title":"\"Closing in on cancer\". The Economist. 16 September 2017. Retrieved 25 September 2017.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false}],"recommendReferences":null,"auditState":2,"lemmaLevel":1,"origin":0,"originEnTitle":null,"originZhTitle":null,"pv":6062,"auditType":0,"synonyms":["放疗"],"showEditTime":"2019.12.13 18:55","auditors":[{"uid":0,"name":"Ki.κe","pic":"https://web.archive.org/web/20221028212143/https://wx.qlogo.cn/mmopen/vi_32/y67kfr32Doib4wg71Jiau7jVWvharic3nRKgdRRQSl6koeQJCo0GQs2Krw0vwdFRsOWnHIQOwAZsSg5lIkIrFCOcQ/132","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false}],"hasZhishiNav":false,"auditInfos":{},"isHistory":false};</script><script crossorigin="anonymous" src="./1137.放射治疗 - 搜狗科学百科_files/aegis.min.js.download"></script><script crossorigin="anonymous" src="./1137.放射治疗 - 搜狗科学百科_files/main_2020092401.js.download"></script><script crossorigin="anonymous" src="./1137.放射治疗 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./1137.放射治疗 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./1137.放射治疗 - 搜狗科学百科_files/jquery-1.11.1.min.js.download"></script><script crossorigin="anonymous" src="./1137.放射治疗 - 搜狗科学百科_files/main_2022062701.js.download"></script><script crossorigin="anonymous" src="./1137.放射治疗 - 搜狗科学百科_files/main_66bbe21.js.download"></script><script crossorigin="anonymous" src="./1137.放射治疗 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./1137.放射治疗 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./1137.放射治疗 - 搜狗科学百科_files/main_edf0f08.js.download"></script><div id="popControl"><div class="pop-control-mask" style="display: none;"><div class="pop-container"><i class="close-icon"></i><div class="stop-title">搜狗科学百科停止服务运营公告</div><div class="stop-user">亲爱的用户：</div><div class="stop-content">因业务方向调整，搜狗科学百科将于2022年11月11日正式停止服务与运营。届时产品内所有数据将依据相关法律进行删除并关闭服务器，您将无法登录及使用搜狗科学百科，相关内容在平台下线后将无法找回。</div><div class="stop-content">搜狗科学百科是由搜狗推出的科学领域专业百科产品，与搜狗百科为两个独立产品，本次停止服务与运营仅对搜狗科学百科，并不影响搜狗百科产品正常使用，敬请知悉。</div><div class="stop-content">由此给您带来的不便我们深表歉意，敬请谅解。再次感谢您一直以来的陪伴与支持！</div><div class="stop-team">搜狗科学百科产品&amp;运营团队</div><div class="stop-time">2022年10月11日</div></div></div></div>
<source>document.getElementById('popControl').style.display = 'none'; </source>
</body></html>